<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:clinigence.com="http://clinigence.com/20230930" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023">
  <link:schemaRef xlink:href="./clnh_taxonomy.zip/clnh_taxonomy/clnh-20230930.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants36Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants36Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ConvertibleNotesPayables1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:IndividualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ConvertibleNotesPayables1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:IndividualsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:IndividualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayables4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:SBALoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ShortTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ShortTermNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ShortTermNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ShortTermNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:ShortTermNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:PPPLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:PPPLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:PPPLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:NotesPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-30</xbrli:startDate>
      <xbrli:endDate>2021-02-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants19Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants19Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants21Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants21Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants22Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants22Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants23Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants23Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants24Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants24Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c132">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c134">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c135">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c136">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants25Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c137">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c138">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants25Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c139">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c140">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c141">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c142">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c143">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants26Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c144">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c145">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c146">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants26Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c147">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c148">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c149">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c150">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants27Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c151">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c152">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants27Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c153">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c154">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c155">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Options12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c156">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c157">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants28Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c158">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c159">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants28Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c160">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c161">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c162">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants29Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c163">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c164">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants29Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c165">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c166">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c167">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">clinigence.com:PopulationHealthPlatformTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c168">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c169">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants30Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c170">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c171">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants30Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c172">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c173">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants31Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c174">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c175">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants31Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c176">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants15Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c177">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants32Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c178">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants15Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c179">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants32Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c180">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c181">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants16Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c182">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants33Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c183">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c184">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants16Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c185">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants33Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c186">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c187">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c188">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c189">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">clinigence.com:ACMGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c190">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c191">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c192">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants17Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c193">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants34Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c194">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants17Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c195">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants34Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c196">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c197">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c198">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants18Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c199">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants35Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c200">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c201">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants18Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c202">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants35Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c203">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c204">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clinigence.com:Warrants1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c205">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:ACMGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c208">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c209">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-09-01</xbrli:startDate>
      <xbrli:endDate>2021-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c210">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c211">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:Noteholder1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c212">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c213">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c214">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:NoteholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c215">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c216">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:OfficersAndEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c218">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:OfficersAndEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c219">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:DirectorsAndOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c223">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clinigence.com:AHPMergerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c225">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c226">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c227">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clinigence.com:AHPMergerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-09-01</xbrli:startDate>
      <xbrli:endDate>2021-09-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c229">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">clinigence.com:CustomersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c230">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholderAndFormerOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ShareholderAndFormerOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clinigence.com:AssumedLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c232">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clinigence.com:AHPMergerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c233">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:MrSternbergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c234">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:MrBowenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c235">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:ElisaLuqmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c236">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:DrHosseinionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c237">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c238">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:LawrenceSchimmelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c239">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:MrBarnettMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c240">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clinigence.com:AHPIPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c241">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clinigence.com:ComputerHardwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c242">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-10-01</xbrli:startDate>
      <xbrli:endDate>2021-10-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c243">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clinigence.com:NoteholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c244">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c245">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c246">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clinigence.com:OfficeEquipmentAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c247">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clinigence.com:OfficeEquipmentAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c248">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">clinigence.com:DevelopmentEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c249">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c250">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-04-01</xbrli:startDate>
      <xbrli:endDate>2021-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c251">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c252">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c253">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c254">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c255">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c256">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-07-01</xbrli:startDate>
      <xbrli:endDate>2021-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c257">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c258">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c259">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c260">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c261">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c262">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c263">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c264">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c265">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c266">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c267">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c268">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c269">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c270">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479681</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:InterestExpense id="f1" decimals="0" contextRef="c1" unitRef="usd">1562107.0</us-gaap:InterestExpense>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f2" decimals="INF" contextRef="c2" unitRef="usd1">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:InvestmentIncomeInterest id="f3" decimals="0" contextRef="c1" unitRef="usd">270.0</us-gaap:InvestmentIncomeInterest>
  <clinigence.com:ExpirationDate id="f4" contextRef="c3">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f5" xsi:nil="true" contextRef="c4" unitRef="usd"/>
  <us-gaap:InvestmentIncomeInterest id="f6" decimals="0" contextRef="c5" unitRef="usd">629.0</us-gaap:InvestmentIncomeInterest>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f7" decimals="INF" contextRef="c6" unitRef="shares">11573231.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f8" xsi:nil="true" contextRef="c7" unitRef="usd"/>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="f9" contextRef="c6">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f10" decimals="INF" contextRef="c6" unitRef="shares">11573231.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:CommonStockCancelled id="f11" xsi:nil="true" contextRef="c8" unitRef="usd"/>
  <us-gaap:InvestmentIncomeInterest id="f12" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:InvestmentIncomeInterest>
  <us-gaap:ConvertibleNotesPayable id="f13" decimals="0" contextRef="c10" unitRef="usd">1965155.0</us-gaap:ConvertibleNotesPayable>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f14" xsi:nil="true" contextRef="c11" unitRef="usd"/>
  <clinigence.com:ConvertibleNotesPayableTextBlock id="f15" contextRef="c5">&lt;p id="xdx_80B_ecustom--ConvertibleNotesPayableTextBlock_zjt41ZFwtnB9" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
10  &lt;span id="xdx_823_zoLr6ciLjAec"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible
notes payable consisted of the following at September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt; 
  &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ConvertibleDebtTableTextBlock_z1WcR5CU3r1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Debt (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zMMMlMLFCez4" style="display: none"&gt;Schedule of Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes payable
    convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $1,965,155
    and $0, respectively; maturing in July 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayables1Member_pp0p0" style="width: 12%; text-align: right" title="Total convertible notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,965,155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayables1Member_zDre4HLkRA84" style="width: 12%; text-align: right" title="Total convertible notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in the liabilities assumed in the AHA merger are convertible promissory notes to various individuals totaling $&lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pp0p0" title="Debt Conversion, Converted Instrument, Amount"&gt;1,965,155&lt;/span&gt; at September
30, 2021. The face value of the notes at issuance was $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pp0p0" title="Debt Instrument, Face Amount"&gt;7,565,375&lt;/span&gt;. The noteholders were granted warrants to purchase the Companys
common stock at $&lt;span id="xdx_903_eus-gaap--SharePrice_c20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pdd" title="Shares price"&gt;1.55&lt;/span&gt; per share in an amount equal to 50% of the shares to be received upon conversion of the Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
debt discount of $&lt;span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pp0p0" title="Debt Discount (Premium)"&gt;7,565,375&lt;/span&gt; is being accreted over 20 months. The accreted balance as of September 30, 2021 is $&lt;span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20210701__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pp0p0" title="Debt Discount (Premium)"&gt;1,965,155&lt;/span&gt;. During the
nine months ended September 30, 2021, various noteholders converted principal balances of $&lt;span id="xdx_902_eus-gaap--AccretionExpense_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pp0p0" title="Accreted balance"&gt;1,150,000&lt;/span&gt; into &lt;span id="xdx_90C_ecustom--CommonStockShares_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndividualsMember_pdd" title="Common stock shares"&gt;933,242&lt;/span&gt; common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
the time of issuance of these notes based on independent valuation, debt discounts were calculated and allocated based on the relative
values of $&lt;span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pp0p0" title="Debt Conversion, Converted Instrument, Amount"&gt;2,658,960&lt;/span&gt; for the value of the warrants and $&lt;span id="xdx_901_ecustom--InterestRateDiscount_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pp0p0" title="Interest rate discount"&gt;4,906,415&lt;/span&gt; related to a beneficial conversion feature. The total debt discount
of $&lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayablesMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Debt Conversion, Converted Instrument, Amount"&gt;3,703,134&lt;/span&gt; is being accreted over 20 months. The accreted balance as of September 30, 2021 is $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFeeAmount_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pp0p0" title="Financing fees paid"&gt;1,086,095&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in the liabilities assumed in the AHA merger are convertible promissory notes to an individual investor totaling $&lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pp0p0" title="Debt Conversion, Converted Instrument, Amount"&gt;575,000&lt;/span&gt;. &lt;span id="xdx_908_ecustom--MergerTransactionDescription_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember" title="Merger transaction description"&gt;The note was
entered into on August 25, 2020 and was convertible into AHAs common stock contingent upon a merger transaction with a SPAC, which
did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and
accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313
shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. On
September 30, 2021, the Company entered into a promissory note settlement agreement whereby the noteholder converted the principal balance
of $575,000 into 191,667 common shares valued at $3.00 per share, and the Company paid $51,750 of accrued interest to the noteholder.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</clinigence.com:ConvertibleNotesPayableTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f16" xsi:nil="true" contextRef="c8" unitRef="usd"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f17" decimals="INF" contextRef="c5" unitRef="shares">14538662.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:InvestmentIncomeInterest id="f18" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:InvestmentIncomeInterest>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f19" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f20" decimals="0" contextRef="c14" unitRef="usd">7565375.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="f21" decimals="0" contextRef="c6" unitRef="usd">122225.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:NotesPayable id="f22" decimals="0" contextRef="c15" unitRef="usd">0.0</us-gaap:NotesPayable>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f23" decimals="0" contextRef="c1" unitRef="usd">-1801967.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f24" xsi:nil="true" contextRef="c16" unitRef="usd"/>
  <us-gaap:InterestExpense id="f25" decimals="0" contextRef="c12" unitRef="usd">332528.0</us-gaap:InterestExpense>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f26" decimals="0" contextRef="c14" unitRef="usd">1965155.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="f27" decimals="INF" contextRef="c6" unitRef="pure">0.0675</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f28" xsi:nil="true" contextRef="c17" unitRef="usd"/>
  <us-gaap:InterestExpense id="f29" decimals="0" contextRef="c5" unitRef="usd">3923246.0</us-gaap:InterestExpense>
  <us-gaap:ConvertibleDebtTableTextBlock id="f30" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ConvertibleDebtTableTextBlock_z1WcR5CU3r1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Debt (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zMMMlMLFCez4" style="display: none"&gt;Schedule of Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes payable
    convertible into Clinigence common shares at $1.55 per share; bearing interest at a rate of 10%; net of debt discount of $1,965,155
    and $0, respectively; maturing in July 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayables1Member_pp0p0" style="width: 12%; text-align: right" title="Total convertible notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,965,155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayables1Member_zDre4HLkRA84" style="width: 12%; text-align: right" title="Total convertible notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="f31" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXKvnQ5bXILa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zDl8HCCORkNg" style="display: none"&gt;Schedule summarizes maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_490_20210930_zFphnNYPU0r7" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;51,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;53,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ReceivableWithImputedInterestNetAmount_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:
    Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,903&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present
    value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;113,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f32" xsi:nil="true" contextRef="c11" unitRef="usd"/>
  <us-gaap:InterestExpense id="f33" decimals="0" contextRef="c9" unitRef="usd">18252.0</us-gaap:InterestExpense>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="f34" decimals="0" contextRef="c6" unitRef="usd">12614.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:ConvertibleNotesPayable id="f35" decimals="0" contextRef="c18" unitRef="usd">0.0</us-gaap:ConvertibleNotesPayable>
  <clinigence.com:CommonStockCancelled id="f36" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:OtherNonoperatingIncomeExpense id="f37" decimals="0" contextRef="c1" unitRef="usd">-977856.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f38" xsi:nil="true" contextRef="c13" unitRef="usd"/>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="f39" decimals="0" contextRef="c6" unitRef="usd">51800.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:DebtInstrumentFaceAmount id="f40" decimals="0" contextRef="c19" unitRef="usd">7565375.0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:OtherNonoperatingIncomeExpense id="f41" decimals="0" contextRef="c5" unitRef="usd">-3163639.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f42" xsi:nil="true" contextRef="c8" unitRef="usd"/>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="f43" decimals="0" contextRef="c6" unitRef="usd">53354.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <dei:DocumentType id="f44" contextRef="c5">10-Q</dei:DocumentType>
  <us-gaap:SharePrice id="f45" decimals="INF" contextRef="c19" unitRef="usd1">1.55</us-gaap:SharePrice>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="f46" decimals="0" contextRef="c6" unitRef="usd">4457.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OtherNonoperatingIncomeExpense id="f47" decimals="0" contextRef="c9" unitRef="usd">-19873.0</us-gaap:OtherNonoperatingIncomeExpense>
  <dei:DocumentTransitionReport id="f48" contextRef="c5">false</dei:DocumentTransitionReport>
  <us-gaap:OtherNonoperatingIncomeExpense id="f49" decimals="0" contextRef="c12" unitRef="usd">-660690.0</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OperatingLeaseLiability id="f50" decimals="0" contextRef="c6" unitRef="usd">113322.0</us-gaap:OperatingLeaseLiability>
  <clinigence.com:MergerTransactionDescription id="f51" contextRef="c20">The note was
entered into on August 25, 2020 and was convertible into AHAs common stock contingent upon a merger transaction with a SPAC, which
did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and
accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313
shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. On
September 30, 2021, the Company entered into a promissory note settlement agreement whereby the noteholder converted the principal balance
of $575,000 into 191,667 common shares valued at $3.00 per share, and the Company paid $51,750 of accrued interest to the noteholder.</clinigence.com:MergerTransactionDescription>
  <us-gaap:ReceivableWithImputedInterestNetAmount id="f52" decimals="0" contextRef="c6" unitRef="usd">8903.0</us-gaap:ReceivableWithImputedInterestNetAmount>
  <us-gaap:AccretionExpense id="f53" decimals="0" contextRef="c14" unitRef="usd">1150000.0</us-gaap:AccretionExpense>
  <dei:DocumentQuarterlyReport id="f54" contextRef="c5">true</dei:DocumentQuarterlyReport>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="f55" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f56" decimals="0" contextRef="c12" unitRef="usd">820978.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <dei:DocumentPeriodEndDate id="f57" contextRef="c5">2021-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f58" decimals="0" contextRef="c5" unitRef="usd">-9074547.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AmortizationOfDebtDiscountPremium id="f59" decimals="0" contextRef="c21" unitRef="usd">1965155.0</us-gaap:AmortizationOfDebtDiscountPremium>
  <dei:EntityFileNumber id="f60" contextRef="c5">000-53862</dei:EntityFileNumber>
  <clinigence.com:ScheduleOfFutureMinimumPaymentsDueUnderNoncancelableLeaseTableTextBlock id="f61" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfFutureMinimumPaymentsDueUnderNoncancelableLeaseTableTextBlock_z8P0jGTezqFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zuoaQdiPsb89" style="display: none"&gt;Schedule minimum payments due under the non-cancelable lease&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_498_20210930_zm5qVuFacmV3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;51,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;53,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0_zqEiVfOQSIlg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,225&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:ScheduleOfFutureMinimumPaymentsDueUnderNoncancelableLeaseTableTextBlock>
  <dei:EntityAddressStateOrProvince id="f62" contextRef="c5">FL</dei:EntityAddressStateOrProvince>
  <us-gaap:OperatingLeasesRentExpenseNet id="f63" decimals="0" contextRef="c22" unitRef="usd">68497.0</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f64" decimals="0" contextRef="c9" unitRef="usd">1756154.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <clinigence.com:CommonStockShares id="f65" decimals="INF" contextRef="c14" unitRef="shares">933242.0</clinigence.com:CommonStockShares>
  <us-gaap:GainLossOnDispositionOfAssets1 id="f66" decimals="0" contextRef="c12" unitRef="usd">142027.0</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths id="f67" decimals="0" contextRef="c6" unitRef="usd">12614.0</us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
  <clinigence.com:InterestRateDiscount id="f68" decimals="0" contextRef="c23" unitRef="usd">4906415.0</clinigence.com:InterestRateDiscount>
  <dei:EntityRegistrantName id="f69" contextRef="c5">Clinigence Holdings, Inc</dei:EntityRegistrantName>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo id="f70" decimals="0" contextRef="c6" unitRef="usd">51800.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
  <dei:EntityAddressAddressLine1 id="f71" contextRef="c5">2455 East Sunrise Blvd.</dei:EntityAddressAddressLine1>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="f72" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f73" decimals="0" contextRef="c23" unitRef="usd">2658960.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <dei:EntityIncorporationStateCountryCode id="f74" contextRef="c5">DE</dei:EntityIncorporationStateCountryCode>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="f75" decimals="0" contextRef="c12" unitRef="usd">39752.0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree id="f76" decimals="0" contextRef="c6" unitRef="usd">53354.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
  <dei:EntityAddressCityOrTown id="f77" contextRef="c5">Fort Lauderdale</dei:EntityAddressCityOrTown>
  <us-gaap:NetIncomeLoss id="f78" decimals="0" contextRef="c1" unitRef="usd">-1801967.0</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour id="f79" decimals="0" contextRef="c6" unitRef="usd">4457.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
  <us-gaap:DebtInstrumentFeeAmount id="f80" decimals="0" contextRef="c24" unitRef="usd">1086095.0</us-gaap:DebtInstrumentFeeAmount>
  <dei:EntityTaxIdentificationNumber id="f81" contextRef="c5">11-3363609</dei:EntityTaxIdentificationNumber>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f82" decimals="0" contextRef="c25" unitRef="usd">3703134.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="f83" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:LeaseCostTableTextBlock id="f84" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--LeaseCostTableTextBlock_z1PiD9r6KzN8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z0GRzm50YZJ7" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease recognized&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20210101__20210930_zyo4pvsdnNni" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included
    in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash
    flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;37,688&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use lease assets
    obtained in the exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--OperatingLeases_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,649&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LongTermDebtTextBlock id="f85" contextRef="c5">&lt;p id="xdx_80B_eus-gaap--LongTermDebtTextBlock_z23oJcrbwvL7" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
11  &lt;span id="xdx_82B_zEIueITv37ac"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes
payable consisted of the following at September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDebtTableTextBlock_zK1xzZfikmbf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_8B8_zGeEXKwXaog" style="display: none"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes
    payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between
    24% and 31%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_d0_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables1Member_zTpalpDcen57" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,765&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SBA
    Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest
    rate of 1%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;432,087&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;311,125&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SBA
    Economic Injury Disaster Loan notes payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables3Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables3Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
    payable with a maturity date of January 31, 2023 and interest rate of 12.9%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables4Member_pp0p0" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;381,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables4Member_zTj64DtVk8mf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NotesPayable_c20210930_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,113,127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NotesPayable_c20201231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;462,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CurrentPortion_iNI_di_c20210930_zFWwBi6i5Mo3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current portion"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(813,127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CurrentPortion_iNI_di_c20201231_zXdOLAlclsfd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current Portion"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(312,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LongTermNotesPayable_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable, net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LongTermNotesPayable_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable, net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning
in April 2018, the Company entered into a series of short-term notes with interest rates ranging from &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ShortTermNotesMember__srt--RangeAxis__srt--MinimumMember_zNprMzCeBJRd" title="Interest rate"&gt;24&lt;/span&gt;% to &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ShortTermNotesMember__srt--RangeAxis__srt--MaximumMember_zi7ewR4NdMmc" title="Interest rate"&gt;31&lt;/span&gt;% per annum. Throughout
the year ended December 31, 2020 the Company made average monthly principal and interest payments approximating $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__custom--ShortTermNotesMember_pp0p0" title="Periodic payments"&gt;8,200&lt;/span&gt; per month. The
outstanding balance on the short-term notes at September 30, 2021 and December 31, 2020 was $&lt;span id="xdx_903_eus-gaap--ShortTermBorrowings_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ShortTermNotesMember_pp0p0" title="Short-term notes"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShortTermBorrowings_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ShortTermNotesMember_pp0p0" title="Short-term notes"&gt;1,765&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Companys long-term debt is comprised of promissory notes pursuant to the Paycheck Protection Program and Economic Injury Disaster
Loan (see below),under Coronavirus Aid, Relief and Economic Security Act (CARES ACT) enacted on March 27, 2020 and
revised under the provisions of the PayCheck Protection Flexibility Act of 2020 on June 5, 2020 andadministered by the United States
Small Business Administration (SBA).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 22, 2020, the Company received loan proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromLoans_c20200501__20200522__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--SBALoanMember_pp0p0" title="Proceeds from loan"&gt;150,000&lt;/span&gt; pursuant to the &lt;span style="color: #333333; letter-spacing: 0.15pt; background-color: white"&gt;U.S.
Small Business Administration (SBA) COVID-19 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;&lt;i&gt;Economic
Injury Disaster Loan&lt;/i&gt; &lt;span style="color: #333333; letter-spacing: 0.15pt"&gt;(EIDL) program. Under the terms of the loan, Borro&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;wer
must pay principal and interest payments of $731 every month beginning Twenty four (24) months from the date of the Note. The SBA will
apply each installment payment first to pay interest accrued to the day the SBA receives the payment and will then apply any remaining
balance to reduce principal. All remaining principal and accrued interest is due and payable Thirty (30) years from the date of the Note.
Borrower may prepay this Note in part or in full at any time, without notice or penalty. AHAs SBA loan of $150,000 was assumed
in the merger transaction under the same terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 21, 2020, the Company received a loan in the amount of $&lt;span id="xdx_901_eus-gaap--ProceedsFromLoans_c20200401__20200421_pp0p0" title="Proceeds from loan"&gt;311,125&lt;/span&gt; under the Payroll Protection Program (PPP Loan).
On February 25, 2021, the Company received a second PPP loan of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromLoans_c20210201__20210225_pp0p0" title="Proceeds from loan"&gt;260,087&lt;/span&gt;. The loans accrue interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200401__20200421_zTNRSNzP13oc" title="Interest rate"&gt;1&lt;/span&gt;% and has an original
maturity date of two years which can be extended to five years by mutual agreement of the Company and SBA. The PPP loan contains
customary events of default relating to, among other things, payment defaults and breaches of representations and warranties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll,
rent and utilities during a designated twenty-four week period. Payments are deferred until the SBA determines the amount to be forgiven.
The Company has utilized the proceeds of the PPP loan in a manner which has enabled qualification as a forgivable loan. However, no assurance
can be provided that all or any portion of the PPP loans will be forgiven. AHAs PPP loan of $&lt;span id="xdx_907_eus-gaap--NotesPayableCurrent_c20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Notes payable"&gt;172,000&lt;/span&gt; was assumed in the merger
transaction under the same terms. On June 21, 2021, the first PPP loan in the amount of $311,125 was forgiven by the SBA and reported
as other income in the consolidated statement of operations. The balance on the PPP loans was $&lt;span id="xdx_90F_eus-gaap--NotesPayableCurrent_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Notes payable"&gt;432,087&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--NotesPayableCurrent_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Notes payable"&gt;311,125&lt;/span&gt; as of September 30,
2021 and December 31, 2020, respectively and has been classified as a long-term liability in notes payable, less current portion on the
accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company assumed a note payable in the AHA merger transaction that AHA entered into with an individual investor on October 24, 2019. AHA
issued a note with a principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pp0p0" title="Face amount"&gt;700,000&lt;/span&gt; and a six-year warrant to purchase an aggregate 1,506,452 shares at a purchase cost
$&lt;span id="xdx_902_ecustom--PurchaseCost_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pp0p0" title="Purchase cost"&gt;50,000&lt;/span&gt; of AHAs common stock at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pdd" title="Exercise price"&gt;1.55&lt;/span&gt; per share, in exchange for $750,000 of total cash proceeds. The Note
bears interest at &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zS6vfPLqfnOh" title="Interest rate"&gt;12.9&lt;/span&gt;% and is subject to optional prepayment by the Company. The Note matured on &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zKOWVpYwm7aj" title="Maturity date"&gt;April 29, 2021&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
February 1, 2021, an Amended and Restated Note was entered into in which the principal amount increased to $&lt;span id="xdx_90F_eus-gaap--NotesPayableCurrent_c20210202_pp0p0" title="Notes payable"&gt;840,000&lt;/span&gt; (original Note plus
the principal amount of Series D Convertible Shares owned by the Investor) which bears interest at &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210130__20210202_zbxQmQ343TDk" title="Interest rate"&gt;12.9&lt;/span&gt;% and matures on January 31, 2023.
The debt premium of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210202_pp0p0" title="Face amount"&gt;840,000&lt;/span&gt; is being accreted over 23 months. The accreted balance as of September 30, 2021 is $&lt;span id="xdx_900_ecustom--PurchaseAggregate_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pdd" title="Purchase aggregate"&gt;381,040&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;







</us-gaap:LongTermDebtTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted id="f86" decimals="INF" contextRef="c1" unitRef="usd1">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OperatingLeasesRentExpenseNet id="f87" decimals="0" contextRef="c26" unitRef="usd">82374.0</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f88" decimals="0" contextRef="c20" unitRef="usd">575000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="f89" decimals="0" contextRef="c1" unitRef="usd">101853.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <dei:EntityAddressAddressLine2 id="f90" contextRef="c5">Suite 1204</dei:EntityAddressAddressLine2>
  <us-gaap:NetIncomeLoss id="f91" decimals="0" contextRef="c12" unitRef="usd">860730.0</us-gaap:NetIncomeLoss>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f92" decimals="INF" contextRef="c12" unitRef="shares">1732687.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ScheduleOfDebtTableTextBlock id="f93" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDebtTableTextBlock_zK1xzZfikmbf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_8B8_zGeEXKwXaog" style="display: none"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes
    payable with maturities between six months and twelve months from the date of issuance with annual percentage interest rates between
    24% and 31%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_d0_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables1Member_zTpalpDcen57" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,765&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SBA
    Paycheck Protection Program notes payable issued in April 2020 and February 2021 with maturity dates through August 2023 and interest
    rate of 1%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;432,087&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;311,125&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SBA
    Economic Injury Disaster Loan notes payable issued in May 2020 with a maturity date of May 2051 and interest rate of 3.75%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables3Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables3Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
    payable with a maturity date of January 31, 2023 and interest rate of 12.9%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesPayable_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables4Member_pp0p0" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;381,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_d0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayables4Member_zTj64DtVk8mf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NotesPayable_c20210930_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,113,127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NotesPayable_c20201231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;462,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CurrentPortion_iNI_di_c20210930_zFWwBi6i5Mo3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current portion"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(813,127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CurrentPortion_iNI_di_c20201231_zXdOLAlclsfd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current Portion"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(312,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LongTermNotesPayable_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable, net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LongTermNotesPayable_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total notes payable, net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:NetIncomeLoss id="f94" decimals="0" contextRef="c5" unitRef="usd">-9074547.0</us-gaap:NetIncomeLoss>
  <us-gaap:NotesPayable id="f95" decimals="0" contextRef="c27" unitRef="usd">432087.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLoss id="f96" decimals="0" contextRef="c9" unitRef="usd">1756154.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="f97" decimals="0" contextRef="c1" unitRef="usd">-1903820.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:OperatingLeasePayments id="f98" decimals="0" contextRef="c5" unitRef="usd">37688.0</us-gaap:OperatingLeasePayments>
  <us-gaap:NotesPayable id="f99" decimals="0" contextRef="c28" unitRef="usd">311125.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="f100" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NotesPayable id="f101" decimals="0" contextRef="c29" unitRef="usd">300000.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="f102" decimals="0" contextRef="c5" unitRef="usd">12343.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <dei:CityAreaCode id="f103" contextRef="c5">954</dei:CityAreaCode>
  <clinigence.com:OperatingLeases id="f104" decimals="0" contextRef="c5" unitRef="usd">16649.0</clinigence.com:OperatingLeases>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="f105" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:EarningsPerShareTextBlock id="f106" contextRef="c5">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zobw6xdPJGHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
8 - &lt;span id="xdx_820_zeuui9vSDV6c"&gt;Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company calculates net income (loss) per common share in accordance with ASC 260 &lt;i&gt;Earnings Per Share&lt;/i&gt; (ASC
260). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common
stockholders by the weighted average number of common shares outstanding during the period. The Companys potentially dilutive
shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation
of diluted net loss per share for the nine months ended September 30, 2021 and 2020 as the result would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zB1jVwG2iduk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zJhaVtJ5MRig" style="display: none"&gt;Computation of diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    shares excluded from calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,538,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,732,687&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:NotesPayable id="f107" decimals="0" contextRef="c30" unitRef="usd">1765.0</us-gaap:NotesPayable>
  <dei:EntityAddressPostalZipCode id="f108" contextRef="c5">33304</dei:EntityAddressPostalZipCode>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f109" decimals="INF" contextRef="c1" unitRef="usd1">-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:NotesPayable id="f110" decimals="0" contextRef="c31" unitRef="usd">150000.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="f111" decimals="0" contextRef="c12" unitRef="usd">860730.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="f112" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zB1jVwG2iduk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zJhaVtJ5MRig" style="display: none"&gt;Computation of diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September
    30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    shares excluded from calculation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,538,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares excluded from calculation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,732,687&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:NotesPayable id="f113" decimals="0" contextRef="c32" unitRef="usd">381040.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="f114" decimals="0" contextRef="c5" unitRef="usd">-9086890.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f115" decimals="INF" contextRef="c33" unitRef="shares">557873.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NotesPayable id="f116" decimals="0" contextRef="c34" unitRef="usd">0.0</us-gaap:NotesPayable>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted id="f117" decimals="0" contextRef="c9" unitRef="usd">1756154.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f118" decimals="INF" contextRef="c35" unitRef="shares">2965431.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NotesPayable id="f119" decimals="0" contextRef="c6" unitRef="usd">1113127.0</us-gaap:NotesPayable>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f120" decimals="INF" contextRef="c1" unitRef="usd1">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f121" decimals="INF" contextRef="c36" unitRef="shares">11573231.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NotesPayable id="f122" decimals="0" contextRef="c37" unitRef="usd">462890.0</us-gaap:NotesPayable>
  <dei:LocalPhoneNumber id="f123" contextRef="c5">449-0641</dei:LocalPhoneNumber>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f124" decimals="INF" contextRef="c12" unitRef="usd1">0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <clinigence.com:CurrentPortion id="f125" decimals="0" contextRef="c6" unitRef="usd">813127.0</clinigence.com:CurrentPortion>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f126" decimals="INF" contextRef="c38" unitRef="shares">1174814.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dei:EntityCurrentReportingStatus id="f127" contextRef="c5">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f128" decimals="INF" contextRef="c5" unitRef="usd1">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:ProceedsFromLoans id="f129" decimals="0" contextRef="c39" unitRef="usd">150000.0</us-gaap:ProceedsFromLoans>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="f130" contextRef="c5">&lt;p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zQWlfmu2PEk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
9  &lt;span id="xdx_82E_zLTpqZGJKXN8"&gt;Stock Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2019, the Company adopted the 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). Awards granted under the 2019
Plan have a ten-year term and may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units,
stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market
value on the date of grant and generally vest over a four year period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
option activity during the nine months ended September 30, 2021 and 2020 follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zHTOf95byqke" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_zx2J1HeSCLx4" style="display: none"&gt;Schedule of stock option activities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    &lt;span style="text-decoration: none"&gt;Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average ExercisePrice&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual Life &lt;span style="text-decoration: none"&gt;(Years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding at December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_z17YBxhSlCg7" style="width: 11%; text-align: right" title="Options, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;48,854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_z9A9tEyIHMyl" style="width: 11%; text-align: right" title="Options, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zzFydY7fhNIg" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930_znHfPc3g46N6" style="text-align: right" title="Options, Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,130,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Options, Granted, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20200930_zod0GTym0WXg" style="text-align: right" title="Options, Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Options, Expired, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20200930_ziRXn21rZOu2" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding atSeptember
    30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200930_zsqvnijjDeH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930_z6yAxSHgcbA9" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_zonOn1zmMD35" style="text-align: right" title="Options, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zxq1tRXG2pfc" style="text-align: right" title="Options, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zxujAlJQw74k" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Options, Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options, Granted, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    assumed in merger&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--OptionsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;490,617&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OptionsAssumedInMergerWeightedAverageExercisePrice_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, assumed in merger, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding atSeptember
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_zf0S9yct6cph" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zQWKlnVnGtg2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_z5Rm20jHwFW1" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;








&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
outstanding at September 30, 2021 consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztC9LNL4Ufd2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&lt;span id="xdx_8BA_zHaGUOoBz0d6" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration
    Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options1Member_zhl0wxaKJGpd" title="Issued Date"&gt;August
    5, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 16%; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 16%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 15%; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options1Member_zZyrmgx0eU9e" title="Options outstanding Expiration Date"&gt;August 5, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options2Member_zBGK3LuZcQP1" title="Issued Date"&gt;October
    29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.0725&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options2Member_zTn1774toCy1" title="Options outstanding Expiration Date"&gt;June 6, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options3Member_zZ98vH2PgLX1" title="Issued Date"&gt;January
    27, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;307,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;307,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options3Member_zR71MgJJ71Pi" title="Options outstanding Expiration Date"&gt;January 27, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options4Member_zLEKu2A7LAq1" title="Issued Date"&gt;January
    27, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options4Member_zTEJxLoYTm61" title="Options outstanding Expiration Date"&gt;January 27, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options5Member_zSB9sXIYNTWb" title="Issued Date"&gt;February
    29, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options5Member_zuabDvijvBu4" title="Options outstanding Expiration Date"&gt;February 28, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options6Member_zpWey7UcmAPg" title="Issued Date"&gt;May
    11, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options6Member_z0xyJ9WNgbwf" title="Options outstanding Expiration Date"&gt;May 11, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options7Member_zDSrLCRIlM5" title="Issued Date"&gt;June
    30, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,056&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,056&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options7Member_zgbUEE6S1IK5" title="Options outstanding Expiration Date"&gt;June 30, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options8Member_zVcRJiAaQeji" title="Issued Date"&gt;January
    28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options8Member_zbf0jRLHK4Ok" title="Options outstanding Expiration Date"&gt;January 28, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options9Member_zLs4nUexMyKj" title="Issued Date"&gt;January
    28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options9Member_ztgSJiQIoGTf" title="Options outstanding Expiration Date"&gt;January 28, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options10Member_zIUUfumyflN6" title="Issued Date"&gt;February
    25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;290,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;290,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options10Member_z9oJF63xoN3d" title="Options outstanding Expiration Date"&gt;March 15, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options11Member_zjNmaKXnTFii" title="Issued Date"&gt;February
    25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options11Member_zm6XAJEUBoP7" title="Options outstanding Expiration Date"&gt;February 25, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zmSVyS672kC"&gt;August
    16, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_z1kzEVdSZA8i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zWLHNC9Lhi09" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zjqlPSDDeWz9" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.51&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zmfklUdMjh01"&gt;August
    16, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2018, the Company issued fully vested warrants to investors as part of a private placement offering. Each unit offered in the private
placement consisted of one share of common stock, and a warrant convertible into 0.4 shares of common stock at an exercise of $1.50 per
whole share. The warrants are exercisable for a period of five years from the date of issuance. The warrants were cancelled on March
1, 2019 and reissued upon the Qualmetrix acquisition and are each convertible into one share of common stock at an exercise price of
$6.67 per share until December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to
which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal
at an exercise price of $5.56 per share with an expiration date of October 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant
activity during the nine months ended September 30, 2021 and 2020 follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z5s7XNE66bm1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zZG0ybRiUG3a" style="display: none"&gt;Schedule of Warrants, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/p&gt; &lt;p style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average &lt;span style="text-decoration: none"&gt;ExercisePrice&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual &lt;span style="text-decoration: none"&gt;Life (Years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding at December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200930_zQsDvdyn5EI5" style="width: 11%; text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,065,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="width: 5%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200930_zJbAtvmSy1c" style="width: 11%; font-size: 12pt; text-align: right" title="Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231_znHpjs5lmy12" title="Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life"&gt;5.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsCancelled_iN_di_c20200101__20200930_zmsa00d6Q3Ck" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(507,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsCancelledPershare_d0_c20200101__20200930_zwPUB0KMDmaj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding
    at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200930_z8G8hpVVS9p2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200930_zCIfF3To0V65" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930_z9cJaMFE8wdi"&gt;4.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210930_zNDT8rS7RRll" style="text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zoatgvQd3LL4" style="text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zOmf6pmNvam3" title="Warrants, Outstanding, Beginning Balance"&gt;3.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsNoWarrantGranted_c20210101__20210930_zBmEenLWJSC1" style="text-align: right" title="Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,648,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsNoWarrantActivityWeightedAverageGranted_c20210101__20210930_zzpbcsLzDmQh" style="text-align: right" title="Warrant Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsNoWarrantExercised_iN_di_c20210101__20210930_zxcMun3rNWG5" style="text-align: right" title="Warrant Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(48,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantsNoWarrantActivityWeightedAverageExercisePrice_c20210101__20210930_zUq2JatO6cle" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    assumed in merger&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,415,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsAssumedInMergerWarrantsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, assumed in merger, Warrants, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding
    at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210930_zNNnl8w4fptf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zuZ4W6cJFo2c" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210930_zGeVzvUbkfGe" title="Warrants, Outstanding, Ending Balance"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
outstanding at September 30, 2021 consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_z8GZwlQcc1Mf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="vertical-align: bottom; text-align: left"&gt;&lt;span id="xdx_8BF_zzN2NNnG4xY4" style="display: none"&gt;Schedule of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 1%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 16%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_zELz2oXEJMR4" title="Issued Date"&gt;March
                                            21, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 16%; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;96,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 16%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;96,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 15%; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_z1jVtd9WUl51" title="Issued Date"&gt;April
                                            30, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_zDQjKN9f682g" title="Issued Date"&gt;May
                                            13, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,393&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,393&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_zvjV08w5zBq1" title="Issued Date"&gt;May
                                            28, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;199,703&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;199,703&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_zzd4k4J3KdY1" title="Issued Date"&gt;June
                                            5, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_zQHGzhK1Eoca" title="Issued Date"&gt;June
                                            25, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_zJj2gDfLHePl" title="Issued Date"&gt;September
                                            6, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_zsVzUYSE2xl1" title="Issued Date"&gt;October
                                            29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member" title="Expiration Date"&gt;February
                                            5, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_zQtgY4gaNpuf" title="Issued Date"&gt;October
                                            29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member" title="Expiration Date"&gt;April
                                            27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_zJ28QkrMCCF9" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,666,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,666,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member" title="Expiration Date"&gt;October
                                            31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_zNHRQcIvVhu8" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member" title="Expiration Date"&gt;February
                                            26, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_z4uceQhGqROe" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,506,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,506,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member" title="Expiration Date"&gt;February
                                            1, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_zmB4WO2lWJFe" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,694,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,694,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member" title="Expiration Date"&gt;July
                                            31, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_z1KV3cOf6nr3" title="Issued Date"&gt;May
                                            14, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;651,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;651,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_z61JfMDuX3H4" title="Issued Date"&gt;May
                                            28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_zq7eH6ZjeCni" title="Issued Date"&gt;June
                                            11, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;182,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;182,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_zoyzRiTrnwfe" title="Issued Date"&gt;June
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;137,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;137,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_zGbyVRnQ72z6" title="Issued Date"&gt;June
                                            24, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;169,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;169,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_z02wsKgo2wOc" title="Issued Date"&gt;June
                                            28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_zLgnnVOJMaf5" title="Issued Date"&gt;June
                                            29, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_zcPtAlEI1CX7" title="Issued Date"&gt;July
                                            6, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zEJ9QcqsVsc" title="Issued Date"&gt;July
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zulz3Tndmlqb" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_z4PbDAwHlMO4" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zqyhZHvRNJEg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zU25jZ7i2cI8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zkRO0kqZqSt" title="Issued Date"&gt;July
                                            29, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zBMe7GhKGYbc" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zdSIsBAnWmYb" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zTyuLdmLb7l2" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zg7rSS4PvNo1" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zefkye3kTnzh" title="Issued Date"&gt;August
                                            6, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_z6LpjqQ3XfJa" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zZbcAl89gSP9" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zV6Vq8PQgjJg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zhxISoHMOar6" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zXT3FmRgkNF1" title="Issued Date"&gt;August
                                            11, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zAN9sq3nKxA" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;128,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zpZYGcP055Oi" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;128,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_z0IuvcD4uNR8" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zvOEy6BoKYqe" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zen8kftpg5aj" title="Issued Date"&gt;August
                                            12, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_z8X4XP4TYySl" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;42,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zHsCuTfxCwBd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;42,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zotz53PTaF3a" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zsQA6Kal3TN8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_zFSNOOT60UId" title="Issued Date"&gt;August
                                            17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z2dxzGpQ5ayi" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z27SpNB6wAj9" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_zOtPToNjcE9c" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z6j5cXY3BYq8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zMal1PriB9ze" title="Issued Date"&gt;August
                                            27, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zhVN5zySgUyi" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_z1sEVDHnRFC7" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zwnxnGJo5G9j" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_z5WsGnZR4qEg" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_z5cZsCscjjIj" title="Issued Date"&gt;August
                                            31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zUCDEnnlZQU6" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zkh5Lz3kFalh" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zRf06XxkhQci" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zYIkPjLL70Z4" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zNBORZfrrMmk" title="Issued Date"&gt;September
                                            1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zWHSrbTcIxzc" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,572&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_z5iw4t4a9pk7" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,572&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zcAWqcG1Ffz3" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zlHlUCWJezJ6" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zQz7zu0cFo3g" title="Issued Date"&gt;September
                                            3, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zPEARedZTWHh" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zRgEGmdOjRM4" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zwgfZQC3vC0c" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zlFDl9Xgkyb3" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zg9KgDOWEqwa" title="Issued Date"&gt;September
                                            9, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zxsNXMRHJjib" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;88,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zdSBjOAsbsQ3" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;88,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_z74OJufwldI" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zvpZgfah4ofa" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zLi66o4i62Zc" title="Issued Date"&gt;September
                                            17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zvUvEisJukP7" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zHX5CZ1nNP1d" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zEJnCyUK9Z9l" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_znv9T40qRn88" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zXksOR8Mc8dl" title="Issued Date"&gt;September
                                            20, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zNkq411DWtV7" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_z8AaN630JEa2" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zNbDAEU6w1Sg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zf9RwVrLBNyi" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zX1bD0tfB0Yd" title="Issued Date"&gt;September
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zMcH8toiB0Bj" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zNTzAAfHB0Kb" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zm7cozV18PQ4" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zJWOCQ2Qnkwe" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zb6Zl6jwvIIf" title="Issued Date"&gt;September
                                            23, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zkPt42WBYldj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zOT591qBXge2" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zOd6kqiawoH5" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_ziqMx1mdGe9i" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;






</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="f131" decimals="INF" contextRef="c40" unitRef="pure">0.24</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <dei:EntityFilerCategory id="f132" contextRef="c5">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f133" decimals="INF" contextRef="c9" unitRef="usd1">0.34</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="f134" decimals="INF" contextRef="c5" unitRef="usd1">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <dei:EntityInteractiveDataCurrent id="f135" contextRef="c5">Yes</dei:EntityInteractiveDataCurrent>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="f136" decimals="INF" contextRef="c1" unitRef="shares">42380274.0</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <clinigence.com:OptionsAssumedInMerger id="f137" decimals="INF" contextRef="c5" unitRef="shares">490617.0</clinigence.com:OptionsAssumedInMerger>
  <us-gaap:ShortTermBorrowings id="f138" decimals="0" contextRef="c41" unitRef="usd">0.0</us-gaap:ShortTermBorrowings>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f139" decimals="INF" contextRef="c12" unitRef="usd1">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <clinigence.com:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 id="f140" contextRef="c12">P8Y4M9D</clinigence.com:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f141" decimals="INF" contextRef="c5" unitRef="usd1">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f142" decimals="INF" contextRef="c37" unitRef="usd1">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <clinigence.com:CurrentPortion id="f143" decimals="0" contextRef="c37" unitRef="usd">312890.0</clinigence.com:CurrentPortion>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare id="f144" decimals="INF" contextRef="c9" unitRef="usd1">0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock id="f145" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zHTOf95byqke" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_zx2J1HeSCLx4" style="display: none"&gt;Schedule of stock option activities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    &lt;span style="text-decoration: none"&gt;Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average ExercisePrice&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual Life &lt;span style="text-decoration: none"&gt;(Years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding at December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_z17YBxhSlCg7" style="width: 11%; text-align: right" title="Options, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;48,854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_z9A9tEyIHMyl" style="width: 11%; text-align: right" title="Options, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zzFydY7fhNIg" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930_znHfPc3g46N6" style="text-align: right" title="Options, Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,130,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Options, Granted, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20200930_zod0GTym0WXg" style="text-align: right" title="Options, Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Options, Expired, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20200930_ziRXn21rZOu2" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding atSeptember
    30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200930_zsqvnijjDeH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20201231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930_z6yAxSHgcbA9" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_zonOn1zmMD35" style="text-align: right" title="Options, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,174,814&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zxq1tRXG2pfc" style="text-align: right" title="Options, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zxujAlJQw74k" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;8.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Options, Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options, Granted, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options
    assumed in merger&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--OptionsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;490,617&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OptionsAssumedInMergerWeightedAverageExercisePrice_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options, assumed in merger, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding atSeptember
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_zf0S9yct6cph" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zQWKlnVnGtg2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_z5Rm20jHwFW1" title="Options, Outstanding, Weighted Average Remaining Contractual Term"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <dei:EntitySmallBusiness id="f146" contextRef="c5">true</dei:EntitySmallBusiness>
  <us-gaap:DebtInstrumentPeriodicPayment id="f147" decimals="0" contextRef="c42" unitRef="usd">8200.0</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f148" decimals="INF" contextRef="c43" unitRef="shares">48854.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <dei:EntityEmergingGrowthCompany id="f149" contextRef="c5">false</dei:EntityEmergingGrowthCompany>
  <us-gaap:EarningsPerShareBasicAndDiluted id="f150" decimals="INF" contextRef="c5" unitRef="usd1">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="f151" decimals="INF" contextRef="c44" unitRef="pure">0.31</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <dei:Security12bTitle id="f152" contextRef="c5">Common     Stock, $0.001 par value</dei:Security12bTitle>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f153" decimals="INF" contextRef="c43" unitRef="usd1">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:EarningsPerShareBasicAndDiluted id="f154" decimals="INF" contextRef="c9" unitRef="usd1">0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="f155" contextRef="c45">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:EarningsPerShareBasicAndDiluted id="f156" decimals="INF" contextRef="c12" unitRef="usd1">0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ProceedsFromLoans id="f157" decimals="0" contextRef="c46" unitRef="usd">311125.0</us-gaap:ProceedsFromLoans>
  <dei:TradingSymbol id="f158" contextRef="c5">CLNH</dei:TradingSymbol>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="f159" decimals="INF" contextRef="c12" unitRef="shares">1130734.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AccountsReceivableNetCurrent id="f160" decimals="0" contextRef="c6" unitRef="usd">432349.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="f161" decimals="0" contextRef="c6" unitRef="usd">393938.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:SharesOutstanding id="f162" decimals="INF" contextRef="c47" unitRef="shares">5282545.0</us-gaap:SharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="f163" decimals="INF" contextRef="c48" unitRef="usd1">1.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <dei:EntityShellCompany id="f164" contextRef="c5">false</dei:EntityShellCompany>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="f165" decimals="INF" contextRef="c12" unitRef="shares">4828014.0</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:EntityCommonStockSharesOutstanding id="f166" decimals="INF" contextRef="c49" unitRef="shares">48027683.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="f167" decimals="INF" contextRef="c12" unitRef="shares">400.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShortTermBorrowings id="f168" decimals="0" contextRef="c50" unitRef="usd">1765.0</us-gaap:ShortTermBorrowings>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="f169" decimals="INF" contextRef="c5" unitRef="shares">33746690.0</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteSubscriptionsReceivable id="f170" decimals="0" contextRef="c6" unitRef="usd">4770000.0</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
  <us-gaap:ProceedsFromLoans id="f171" decimals="0" contextRef="c51" unitRef="usd">260087.0</us-gaap:ProceedsFromLoans>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="f172" decimals="INF" contextRef="c48" unitRef="usd1">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f173" decimals="0" contextRef="c6" unitRef="usd">6011442.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NotesPayableCurrent id="f174" decimals="0" contextRef="c52" unitRef="usd">172000.0</us-gaap:NotesPayableCurrent>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="f175" decimals="INF" contextRef="c9" unitRef="shares">5179342.0</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="f176" decimals="INF" contextRef="c12" unitRef="shares">4374.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f177" decimals="0" contextRef="c37" unitRef="usd">26931.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="f178" decimals="INF" contextRef="c46" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="f179" decimals="INF" contextRef="c48" unitRef="usd1">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f180" decimals="0" contextRef="c53" unitRef="usd">-18218962.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:NotesPayableCurrent id="f181" decimals="0" contextRef="c54" unitRef="usd">432087.0</us-gaap:NotesPayableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="f182" decimals="0" contextRef="c6" unitRef="usd">9398.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f183" decimals="INF" contextRef="c55" unitRef="shares">1174814.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f184" decimals="0" contextRef="c56" unitRef="usd">17079885.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:NotesPayableCurrent id="f185" decimals="0" contextRef="c57" unitRef="usd">311125.0</us-gaap:NotesPayableCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="f186" decimals="INF" contextRef="c5" unitRef="shares">1300000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AccountsReceivableNetCurrent id="f187" decimals="0" contextRef="c37" unitRef="usd">18283.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f188" decimals="0" contextRef="c47" unitRef="usd">5282.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="f189" contextRef="c48">P8Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <clinigence.com:PurchaseCost id="f190" decimals="0" contextRef="c58" unitRef="usd">50000.0</clinigence.com:PurchaseCost>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f191" decimals="INF" contextRef="c59" unitRef="shares">932567.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:DebtInstrumentFaceAmount id="f192" decimals="0" contextRef="c60" unitRef="usd">700000.0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:AssetsCurrent id="f193" decimals="0" contextRef="c6" unitRef="usd">11607729.0</us-gaap:AssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f194" decimals="INF" contextRef="c37" unitRef="shares">1174814.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <clinigence.com:CommonStockIssuedForRelatedPartyNoteShares id="f195" decimals="INF" contextRef="c59" unitRef="shares">46154.0</clinigence.com:CommonStockIssuedForRelatedPartyNoteShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f196" decimals="INF" contextRef="c6" unitRef="usd1">1.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f197" decimals="0" contextRef="c61" unitRef="usd">3852637.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="f198" contextRef="c5">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:DebtInstrumentMaturityDate id="f199" contextRef="c58">2021-04-29</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:StockholdersEquityNoteSubscriptionsReceivable id="f200" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f201" decimals="0" contextRef="c62" unitRef="usd">3851704.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="f202" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztC9LNL4Ufd2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&lt;span id="xdx_8BA_zHaGUOoBz0d6" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration
    Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options1Member_zhl0wxaKJGpd" title="Issued Date"&gt;August
    5, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 16%; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 16%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,480&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options1Member_pdd" style="width: 15%; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options1Member_zZyrmgx0eU9e" title="Options outstanding Expiration Date"&gt;August 5, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options2Member_zBGK3LuZcQP1" title="Issued Date"&gt;October
    29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options2Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.0725&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options2Member_zTn1774toCy1" title="Options outstanding Expiration Date"&gt;June 6, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options3Member_zZ98vH2PgLX1" title="Issued Date"&gt;January
    27, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;307,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;307,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options3Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options3Member_zR71MgJJ71Pi" title="Options outstanding Expiration Date"&gt;January 27, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options4Member_zLEKu2A7LAq1" title="Issued Date"&gt;January
    27, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options4Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options4Member_zTEJxLoYTm61" title="Options outstanding Expiration Date"&gt;January 27, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options5Member_zSB9sXIYNTWb" title="Issued Date"&gt;February
    29, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options5Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options5Member_zuabDvijvBu4" title="Options outstanding Expiration Date"&gt;February 28, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options6Member_zpWey7UcmAPg" title="Issued Date"&gt;May
    11, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options6Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options6Member_z0xyJ9WNgbwf" title="Options outstanding Expiration Date"&gt;May 11, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options7Member_zDSrLCRIlM5" title="Issued Date"&gt;June
    30, 2020&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,056&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,056&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options7Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options7Member_zgbUEE6S1IK5" title="Options outstanding Expiration Date"&gt;June 30, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options8Member_zVcRJiAaQeji" title="Issued Date"&gt;January
    28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options8Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options8Member_zbf0jRLHK4Ok" title="Options outstanding Expiration Date"&gt;January 28, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options9Member_zLs4nUexMyKj" title="Issued Date"&gt;January
    28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options9Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options9Member_ztgSJiQIoGTf" title="Options outstanding Expiration Date"&gt;January 28, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options10Member_zIUUfumyflN6" title="Issued Date"&gt;February
    25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;290,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;290,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options10Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options10Member_z9oJF63xoN3d" title="Options outstanding Expiration Date"&gt;March 15, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options11Member_zjNmaKXnTFii" title="Issued Date"&gt;February
    25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--Options11Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options11Member_zm6XAJEUBoP7" title="Options outstanding Expiration Date"&gt;February 25, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--IssuedDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zmSVyS672kC"&gt;August
    16, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_z1kzEVdSZA8i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zWLHNC9Lhi09" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zjqlPSDDeWz9" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.51&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--OptionsOutstandingExpirationDate_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Options12Member_zmfklUdMjh01"&gt;August
    16, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,431&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="f203" decimals="INF" contextRef="c58" unitRef="pure">0.129</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DepositsAssets id="f204" decimals="0" contextRef="c6" unitRef="usd">0.0</us-gaap:DepositsAssets>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f205" decimals="0" contextRef="c59" unitRef="usd">933.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NotesPayableCurrent id="f206" decimals="0" contextRef="c63" unitRef="usd">840000.0</us-gaap:NotesPayableCurrent>
  <clinigence.com:IssuedDate id="f207" contextRef="c64">2020-01-27</clinigence.com:IssuedDate>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="f208" decimals="0" contextRef="c37" unitRef="usd">111842.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <clinigence.com:CommonStockIssuedForRelatedPartyNote id="f209" decimals="0" contextRef="c61" unitRef="usd">30000.0</clinigence.com:CommonStockIssuedForRelatedPartyNote>
  <clinigence.com:OptionsAssumedInMergerWeightedAverageExercisePrice id="f210" decimals="INF" contextRef="c5" unitRef="usd1">2.0</clinigence.com:OptionsAssumedInMergerWeightedAverageExercisePrice>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f211" decimals="INF" contextRef="c60" unitRef="usd1">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:Investments id="f212" decimals="0" contextRef="c6" unitRef="usd">7578171.0</us-gaap:Investments>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="f213" decimals="INF" contextRef="c65" unitRef="pure">0.129</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <clinigence.com:CommonStockIssuedForRelatedPartyNote id="f214" decimals="0" contextRef="c62" unitRef="usd">29954.0</clinigence.com:CommonStockIssuedForRelatedPartyNote>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f215" decimals="INF" contextRef="c6" unitRef="shares">2965431.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <clinigence.com:CommonStockIssuedForRelatedPartyNote id="f216" decimals="0" contextRef="c59" unitRef="usd">46.0</clinigence.com:CommonStockIssuedForRelatedPartyNote>
  <us-gaap:AssetsCurrent id="f217" decimals="0" contextRef="c37" unitRef="usd">157056.0</us-gaap:AssetsCurrent>
  <clinigence.com:PurchaseAggregate id="f218" decimals="INF" contextRef="c58" unitRef="shares">381040.0</clinigence.com:PurchaseAggregate>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f219" decimals="0" contextRef="c6" unitRef="usd">108842.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="f220" decimals="INF" contextRef="c59" unitRef="shares">33034466.0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <clinigence.com:OptionsOutstandingExpirationDate id="f221" contextRef="c66">2029-08-05</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:ProfitLoss id="f222" decimals="0" contextRef="c67" unitRef="usd">-4444559.0</us-gaap:ProfitLoss>
  <clinigence.com:IssuedDate id="f223" contextRef="c68">2019-10-29</clinigence.com:IssuedDate>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f224" decimals="0" contextRef="c61" unitRef="usd">68051012.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:DebtInstrumentFaceAmount id="f225" decimals="0" contextRef="c63" unitRef="usd">840000.0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PropertyPlantAndEquipmentNet id="f226" decimals="0" contextRef="c37" unitRef="usd">12391.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f227" decimals="0" contextRef="c62" unitRef="usd">68017978.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <clinigence.com:IssuedDate id="f228" contextRef="c66">2019-08-05</clinigence.com:IssuedDate>
  <us-gaap:CommonStockSharesSubscriptions id="f229" decimals="0" contextRef="c6" unitRef="usd">6228571.0</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f230" decimals="INF" contextRef="c69" unitRef="shares">40480.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f231" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f232" decimals="0" contextRef="c59" unitRef="usd">33034.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:ProfitLoss id="f233" decimals="0" contextRef="c70" unitRef="usd">-39581.0</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f234" decimals="INF" contextRef="c69" unitRef="shares">40480.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <clinigence.com:CashAndIssuedWarrants id="f235" decimals="INF" contextRef="c6" unitRef="shares">1534287.0</clinigence.com:CashAndIssuedWarrants>
  <us-gaap:ProfitLoss id="f236" decimals="0" contextRef="c61" unitRef="usd">-4484140.0</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f237" decimals="INF" contextRef="c69" unitRef="usd1">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharesOutstanding id="f238" decimals="INF" contextRef="c71" unitRef="shares">39295732.0</us-gaap:SharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f239" decimals="INF" contextRef="c72" unitRef="usd1">0.0725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:IntangibleAssetsCurrent id="f240" decimals="0" contextRef="c6" unitRef="usd">9269694.0</us-gaap:IntangibleAssetsCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f241" decimals="0" contextRef="c71" unitRef="usd">39295.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f242" decimals="INF" contextRef="c72" unitRef="shares">3600.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f243" contextRef="c5">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1aY1v5mfGBj" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
12  &lt;span id="xdx_825_zKn33Us5QPib"&gt;Stock Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company sold &lt;span id="xdx_904_eus-gaap--CommonStockSharesSubscriptions_c20210930_pp0p0" title="Common stock shares sold"&gt;6,228,571&lt;/span&gt; common shares consisting of 1,000,000 shares valued at $3.00 per share to a strategic investor and 5,228,571 valued
at $&lt;span id="xdx_90B_eus-gaap--SharePrice_c20210930_pdd" title="Shares issued price"&gt;1.75&lt;/span&gt; per share to various investors for proceeds totaling $&lt;span id="xdx_90F_ecustom--InvestorsForProceeds_c20210701__20210930_pp0p0" title="Investors for proceeds"&gt;12,150,000&lt;/span&gt; during the nine months ended September 30, 2021. The Company
received $4,770,000 of the proceeds in October 2021 and recorded a receivable at September 30, 2021. The Company paid the placement agent
$&lt;span id="xdx_90F_ecustom--PlacementAgent_c20210930_pp0p0" title="Placement agent"&gt;678,000&lt;/span&gt; in cash and issued &lt;span id="xdx_905_ecustom--CashAndIssuedWarrants_c20210930_pdd" title="Cash and issued warrants"&gt;1,534,287&lt;/span&gt; warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company sold &lt;span id="xdx_900_eus-gaap--CommonStockSharesSubscriptions_iI_pp0p0_c20210928_zfn4BpcdbxWg"&gt;1,250&lt;/span&gt; common shares valued at $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20210928_zN4hniZzbCCi"&gt;1.25&lt;/span&gt; per share to a director for proceeds of $&lt;span id="xdx_900_ecustom--InvestorsForProceeds_pp0p0_c20210901__20210928_zfVf8rySzs0i"&gt;1,562&lt;/span&gt; on September 28, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the convertible notes payable (see Note 11 above) various noteholders converted $&lt;span id="xdx_900_ecustom--ConvertedWarrants_pp0p0_c20210101__20210930_ziV3CJXb2lP5" title="Converted warrants"&gt;1,725,000&lt;/span&gt; of principal balance to &lt;span id="xdx_907_ecustom--CommonStockShare_c20210101__20210930_zFh9x7oqX7o7" title="Common stock shares"&gt;933,242&lt;/span&gt;
shares of common stock during the nine months ended September 30, 2021. The stock issued was determined based on the terms of the convertible
notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the acquisition of AHA the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210201__20210225__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Common Stock Issued for acquisition, shares"&gt;14,198,615&lt;/span&gt; common shares valued at $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_c20210225__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Sale of Stock price per share"&gt;2.06&lt;/span&gt; per share to the shareholders of AHA
on February 25, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the acquisition of AHP the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210201__20210225__dei--LegalEntityAxis__custom--AHPMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Common Stock Issued for acquisition, shares"&gt;19,000,000&lt;/span&gt; common shares valued at $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_c20210225__dei--LegalEntityAxis__custom--AHPMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Sale of Stock price per share"&gt;2.06&lt;/span&gt; per share to the shareholders of AHP
on February 25, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the AHA and AHP acquisitions, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210201__20210225__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Common Stock Issued for services"&gt;750,000&lt;/span&gt; common shares valued at $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20210225__dei--LegalEntityAxis__custom--AHAMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersMember_pdd" title="Share price per share"&gt;2.06&lt;/span&gt; per share for consulting services
on February 25, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 28, 2021, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210101__20210128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndEmployeesMember_pdd" title="Shares issued for share based compensation, shares"&gt;228,721&lt;/span&gt; common shares to officers and employees for deferred salaries and bonuses and reimbursed
expenses, including &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210101__20210128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndOfficersMember_pdd" title="Shares issued for share based compensation, shares"&gt;153,606&lt;/span&gt; common shares issued to directors and officers, valued at $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_c20210128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndEmployeesMember_pdd" title="Share price per share"&gt;.65&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f244" decimals="0" contextRef="c73" unitRef="usd">88979521.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f245" decimals="INF" contextRef="c72" unitRef="shares">3600.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharePrice id="f246" decimals="INF" contextRef="c6" unitRef="usd1">1.75</us-gaap:SharePrice>
  <us-gaap:Investments id="f247" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:Investments>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f248" decimals="0" contextRef="c74" unitRef="usd">-22663521.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DepositsAssets id="f249" decimals="0" contextRef="c37" unitRef="usd">410.0</us-gaap:DepositsAssets>
  <clinigence.com:OptionsOutstandingExpirationDate id="f250" contextRef="c68">2027-06-06</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f251" decimals="0" contextRef="c75" unitRef="usd">-39581.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <clinigence.com:InvestorsForProceeds id="f252" decimals="0" contextRef="c1" unitRef="usd">12150000.0</clinigence.com:InvestorsForProceeds>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f253" decimals="INF" contextRef="c76" unitRef="shares">307884.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:Goodwill id="f254" decimals="0" contextRef="c6" unitRef="usd">54697684.0</us-gaap:Goodwill>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f255" decimals="0" contextRef="c77" unitRef="usd">66315714.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:CommonStockSharesSubscriptions id="f256" decimals="0" contextRef="c78" unitRef="usd">1250.0</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f257" decimals="0" contextRef="c79" unitRef="usd">1826.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:IntangibleAssetsCurrent id="f258" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:IntangibleAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f259" decimals="INF" contextRef="c76" unitRef="shares">307884.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:SharePrice id="f260" decimals="INF" contextRef="c78" unitRef="usd1">1.25</us-gaap:SharePrice>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f261" decimals="INF" contextRef="c79" unitRef="shares">1825714.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:Goodwill id="f262" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:Goodwill>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f263" decimals="INF" contextRef="c76" unitRef="usd1">1.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <clinigence.com:PlacementAgent id="f264" decimals="0" contextRef="c6" unitRef="usd">678000.0</clinigence.com:PlacementAgent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f265" decimals="0" contextRef="c6" unitRef="usd">45440.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:Revenues id="f266" decimals="0" contextRef="c1" unitRef="usd">5568757.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f267" decimals="0" contextRef="c80" unitRef="usd">4875.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy id="f268" contextRef="c5">&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zJiP6GdcAwCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zm24XLFXgBHl"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill
represents the net identifiable assets acquired and the liabilities assumed of AHA and AHP and the fair market value of the common shares
issued by the Company for the acquisition of AHA and AHP. In accordance with ASC Topic No. 350 Intangibles  Goodwill and
Other), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value
based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss
is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be
sufficient to recover the assets carrying amount, an impairment loss is charged to expense in the period identified. No impairment
was recorded during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <clinigence.com:IssuedDate id="f269" contextRef="c81">2020-01-27</clinigence.com:IssuedDate>
  <us-gaap:AccruedLiabilitiesCurrent id="f270" decimals="0" contextRef="c6" unitRef="usd">181935.0</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f271" decimals="0" contextRef="c6" unitRef="usd">83271518.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:SharesOutstanding id="f272" decimals="INF" contextRef="c80" unitRef="shares">4874999.0</us-gaap:SharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f273" decimals="INF" contextRef="c82" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f274" decimals="INF" contextRef="c83" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:ConvertibleInstrumentsPoliciesTextBlock id="f275" contextRef="c5">&lt;p id="xdx_848_ecustom--ConvertibleInstrumentsPoliciesTextBlock_zW2zhiG4MGS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zQ86CyDz1Sl2"&gt;Convertible
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging Activities.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Applicable
GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative
financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and
risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host
contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at
fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same
terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated
from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value
of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at
the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements
are amortized over the term of the related debt to their stated date of maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</clinigence.com:ConvertibleInstrumentsPoliciesTextBlock>
  <clinigence.com:OptionsOutstandingExpirationDate id="f276" contextRef="c64">2030-01-27</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:Revenues id="f277" decimals="0" contextRef="c12" unitRef="usd">1194250.0</us-gaap:Revenues>
  <us-gaap:ProfitLoss id="f278" decimals="0" contextRef="c84" unitRef="usd">227306.0</us-gaap:ProfitLoss>
  <clinigence.com:ExpirationDate id="f279" contextRef="c85">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f280" contextRef="c86">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <us-gaap:DueToRelatedPartiesCurrent id="f281" decimals="0" contextRef="c6" unitRef="usd">128176.0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f282" decimals="INF" contextRef="c87" unitRef="shares">225000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CostOfRevenue id="f283" decimals="0" contextRef="c1" unitRef="usd">4380671.0</us-gaap:CostOfRevenue>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f284" decimals="INF" contextRef="c88" unitRef="shares">14393.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f285" decimals="INF" contextRef="c89" unitRef="shares">45714.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ProfitLoss id="f286" decimals="0" contextRef="c90" unitRef="usd">227306.0</us-gaap:ProfitLoss>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="f287" contextRef="c91">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:Assets id="f288" decimals="0" contextRef="c6" unitRef="usd">83271518.0</us-gaap:Assets>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f289" contextRef="c92">2019-05-13</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f290" contextRef="c93">2021-06-29</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f291" decimals="0" contextRef="c94" unitRef="usd">16689042.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f292" decimals="INF" contextRef="c87" unitRef="shares">225000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f293" decimals="INF" contextRef="c88" unitRef="shares">14393.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f294" decimals="INF" contextRef="c89" unitRef="shares">45714.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f295" decimals="0" contextRef="c6" unitRef="usd">3330337.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f296" decimals="0" contextRef="c37" unitRef="usd">169857.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f297" decimals="INF" contextRef="c87" unitRef="usd1">1.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f298" decimals="0" contextRef="c95" unitRef="usd">-13464219.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:Revenues id="f299" decimals="0" contextRef="c5" unitRef="usd">12873607.0</us-gaap:Revenues>
  <clinigence.com:IssuedDate id="f300" contextRef="c96">2020-02-29</clinigence.com:IssuedDate>
  <us-gaap:Assets id="f301" decimals="0" contextRef="c37" unitRef="usd">169857.0</us-gaap:Assets>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f302" decimals="0" contextRef="c97" unitRef="usd">3229698.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="f303" contextRef="c98">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f304" decimals="INF" contextRef="c88" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f305" decimals="INF" contextRef="c89" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:OptionsOutstandingExpirationDate id="f306" contextRef="c81">2027-01-27</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:CustomerDepositsCurrent id="f307" decimals="0" contextRef="c6" unitRef="usd">25326.0</us-gaap:CustomerDepositsCurrent>
  <clinigence.com:CommonStockCancelled id="f308" decimals="0" contextRef="c99" unitRef="usd">-23.0</clinigence.com:CommonStockCancelled>
  <clinigence.com:ExpirationDate id="f309" contextRef="c92">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f310" contextRef="c93">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <us-gaap:Revenues id="f311" decimals="0" contextRef="c9" unitRef="usd">350032.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f312" decimals="INF" contextRef="c100" unitRef="shares">95794.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ResearchAndDevelopmentExpense id="f313" decimals="0" contextRef="c1" unitRef="usd">72266.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f314" decimals="INF" contextRef="c99" unitRef="shares">190476.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="f315" contextRef="c5">&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoyEeXfQLWtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z9DdplJkeAT1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, &lt;i&gt;Awards
Classified as Equity,&lt;/i&gt; which requires the measurement of compensation expense for all share-based compensation granted to employees
and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period
for awards expected to vest.The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock
options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected
stock price volatility of the Companys common stock, the risk free interest rate at the date of grant, the expected vesting term
of the grant, expected dividends, and an assumption related to forfeitures of such grants.Changes in these subjective input
assumptions can materially affect the fair value estimate of the Companys stock options and warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f316" decimals="INF" contextRef="c101" unitRef="shares">199703.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f317" decimals="INF" contextRef="c102" unitRef="shares">28571.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f318" decimals="0" contextRef="c37" unitRef="usd">695424.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:GrossProfit id="f319" decimals="0" contextRef="c1" unitRef="usd">1188086.0</us-gaap:GrossProfit>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f320" decimals="0" contextRef="c99" unitRef="usd">190.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f321" contextRef="c103">2019-05-28</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f322" contextRef="c104">2021-07-06</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DeferredRevenueCurrent id="f323" decimals="0" contextRef="c6" unitRef="usd">45022.0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f324" decimals="INF" contextRef="c100" unitRef="shares">95794.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <dei:EntityCentralIndexKey id="f325" contextRef="c5">0001479681</dei:EntityCentralIndexKey>
  <us-gaap:CostOfRevenue id="f326" decimals="0" contextRef="c12" unitRef="usd">674881.0</us-gaap:CostOfRevenue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f327" decimals="INF" contextRef="c101" unitRef="shares">199703.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f328" decimals="INF" contextRef="c102" unitRef="shares">28571.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f329" decimals="0" contextRef="c105" unitRef="usd">119810.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="f330" contextRef="c5">&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zecMDEU15Uu2" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zzeRDV3mk5A"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances
dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets,
the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or
factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the
Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level
for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is
less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and
its estimated fair value, generally measured by the present value of the estimated cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f331" decimals="INF" contextRef="c100" unitRef="usd1">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <dei:CurrentFiscalYearEndDate id="f332" contextRef="c5">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:CustomerDepositsCurrent id="f333" decimals="0" contextRef="c37" unitRef="usd">38651.0</us-gaap:CustomerDepositsCurrent>
  <us-gaap:CostOfRevenue id="f334" decimals="0" contextRef="c5" unitRef="usd">10156087.0</us-gaap:CostOfRevenue>
  <us-gaap:RevenueRecognitionDeferredRevenue id="f335" contextRef="c5">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDeferredRevenue_zSoLwGpSt7ci" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z6n8wPjLxI47"&gt;Deferred
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deposits
from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when
cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily
convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue
item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Companys support and maintenance
services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various
customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $&lt;span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_c20210930_pp0p0" title="Deferred revenue"&gt;45,022&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--DeferredRevenueCurrent_c20201231_pp0p0" title="Deferred revenue"&gt;76,687&lt;/span&gt; as of
September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionDeferredRevenue>
  <clinigence.com:IssuedDate id="f336" contextRef="c106">2020-05-11</clinigence.com:IssuedDate>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f337" decimals="0" contextRef="c9" unitRef="usd">120000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f338" decimals="INF" contextRef="c101" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f339" decimals="INF" contextRef="c102" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:CostOfRevenue id="f340" decimals="0" contextRef="c9" unitRef="usd">210894.0</us-gaap:CostOfRevenue>
  <clinigence.com:OptionsOutstandingExpirationDate id="f341" contextRef="c96">2030-02-28</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:AccruedLiabilitiesCurrent id="f342" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:AccruedLiabilitiesCurrent>
  <clinigence.com:ExpirationDate id="f343" contextRef="c103">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f344" contextRef="c104">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:OperatingExpenses id="f345" decimals="0" contextRef="c1" unitRef="usd">2012197.0</us-gaap:OperatingExpenses>
  <clinigence.com:CommonStockCancelledShares id="f346" decimals="INF" contextRef="c99" unitRef="shares">-23276.0</clinigence.com:CommonStockCancelledShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f347" decimals="INF" contextRef="c107" unitRef="shares">380000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <dei:AmendmentFlag id="f348" contextRef="c5">false</dei:AmendmentFlag>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f349" decimals="INF" contextRef="c108" unitRef="shares">7197.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f350" decimals="INF" contextRef="c109" unitRef="shares">12857.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:GrossProfit id="f351" decimals="0" contextRef="c12" unitRef="usd">519369.0</us-gaap:GrossProfit>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="f352" decimals="INF" contextRef="c99" unitRef="shares">240346.0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f353" contextRef="c110">2019-06-05</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f354" contextRef="c111">2021-07-22</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:GrossProfit id="f355" decimals="0" contextRef="c5" unitRef="usd">2717520.0</us-gaap:GrossProfit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f356" decimals="INF" contextRef="c107" unitRef="shares">380000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f357" decimals="INF" contextRef="c108" unitRef="shares">7197.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f358" decimals="INF" contextRef="c109" unitRef="shares">12857.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <dei:DocumentFiscalYearFocus id="f359" contextRef="c5">2021</dei:DocumentFiscalYearFocus>
  <us-gaap:DueToRelatedPartiesCurrent id="f360" decimals="0" contextRef="c37" unitRef="usd">30000.0</us-gaap:DueToRelatedPartiesCurrent>
  <clinigence.com:CommonStockCancelled id="f361" decimals="0" contextRef="c9" unitRef="usd">-33750.0</clinigence.com:CommonStockCancelled>
  <us-gaap:IncomeTaxPolicyTextBlock id="f362" contextRef="c5">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zDhTCNPcSeL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_znQeHywjaQr7"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Under
this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets
and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected
to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain
tax positions recognized in the Companys financial statements&lt;i&gt;.&lt;/i&gt; In accordance with this provision, tax positions must meet
a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax
position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f363" decimals="INF" contextRef="c107" unitRef="usd1">1.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <dei:DocumentFiscalPeriodFocus id="f364" contextRef="c5">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:GrossProfit id="f365" decimals="0" contextRef="c9" unitRef="usd">139138.0</us-gaap:GrossProfit>
  <clinigence.com:IssuedDate id="f366" contextRef="c112">2020-06-30</clinigence.com:IssuedDate>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f367" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f368" decimals="INF" contextRef="c108" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f369" decimals="INF" contextRef="c109" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:CommonStockCancelled id="f370" decimals="0" contextRef="c105" unitRef="usd">-33727.0</clinigence.com:CommonStockCancelled>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="f371" contextRef="c5">&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5exxHHnrha3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_znA54wOCBLI1"&gt;Fair
Value Measurements&lt;/span&gt; &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company adopted the provisions of ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The
carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations,
which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded
conversion options, are comparable to rates of returns for instruments of similar credit risk. The Companys investment in AHA
was valued at level 3 input.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1  quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2  quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3  inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/p&gt;





</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <clinigence.com:OptionsOutstandingExpirationDate id="f372" contextRef="c106">2027-05-11</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:ConvertibleDebtCurrent id="f373" decimals="0" contextRef="c6" unitRef="usd">1965155.0</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ResearchAndDevelopmentExpense id="f374" decimals="0" contextRef="c5" unitRef="usd">208615.0</us-gaap:ResearchAndDevelopmentExpense>
  <clinigence.com:ExpirationDate id="f375" contextRef="c110">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f376" contextRef="c111">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:AdvertisingCostsPolicyTextBlock id="f377" contextRef="c5">&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zwXebGwEdegg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_z4JCsuLQWVy7"&gt;Advertising
Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses advertising costs as incurred. Advertising costs of $&lt;span id="xdx_906_eus-gaap--AdvertisingExpense_c20210101__20210930_pp0p0" title="Advertising costs"&gt;21,154&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20200101__20200930_pp0p0" title="Advertising costs"&gt;41,418&lt;/span&gt; were charged to operations for the nine months
ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f378" decimals="INF" contextRef="c113" unitRef="shares">122056.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f379" xsi:nil="true" contextRef="c114" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f380" decimals="INF" contextRef="c115" unitRef="shares">208361.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f381" decimals="INF" contextRef="c116" unitRef="shares">71428.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:PreferredStockSharesIssued id="f382" decimals="INF" contextRef="c6" unitRef="shares">0.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ProfitLoss id="f383" decimals="0" contextRef="c11" unitRef="usd">1756154.0</us-gaap:ProfitLoss>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f384" contextRef="c117">2019-06-25</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f385" contextRef="c118">2021-07-29</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:ResearchAndDevelopmentExpense id="f386" decimals="0" contextRef="c9" unitRef="usd">73827.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f387" decimals="INF" contextRef="c113" unitRef="shares">122056.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f388" xsi:nil="true" contextRef="c119" unitRef="usd"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f389" decimals="0" contextRef="c9" unitRef="usd">305000.0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:AdvertisingExpense id="f390" decimals="0" contextRef="c5" unitRef="usd">21154.0</us-gaap:AdvertisingExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f391" decimals="INF" contextRef="c115" unitRef="shares">208361.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f392" decimals="INF" contextRef="c116" unitRef="shares">71428.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ResearchAndDevelopmentExpense id="f393" decimals="0" contextRef="c12" unitRef="usd">502961.0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f394" decimals="INF" contextRef="c113" unitRef="usd1">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f395" decimals="0" contextRef="c105" unitRef="usd">304760.0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f396" contextRef="c5">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXJnGtHtdT08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zFs0qXSMXrC4"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect
is expected on the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <clinigence.com:IssuedDate id="f397" contextRef="c120">2021-01-28</clinigence.com:IssuedDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f398" decimals="INF" contextRef="c115" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f399" decimals="INF" contextRef="c116" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:SellingAndMarketingExpenses id="f400" decimals="0" contextRef="c1" unitRef="usd">4711.0</clinigence.com:SellingAndMarketingExpenses>
  <clinigence.com:OptionsOutstandingExpirationDate id="f401" contextRef="c112">2030-06-30</clinigence.com:OptionsOutstandingExpirationDate>
  <clinigence.com:ExpirationDate id="f402" contextRef="c118">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:DeferredRevenueCurrent id="f403" decimals="0" contextRef="c37" unitRef="usd">76687.0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="f404" decimals="0" contextRef="c99" unitRef="usd">240.0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:FurnitureAndFixturesGross id="f405" decimals="0" contextRef="c37" unitRef="usd">5300.0</us-gaap:FurnitureAndFixturesGross>
  <clinigence.com:ExpirationDate id="f406" contextRef="c117">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f407" xsi:nil="true" contextRef="c121" unitRef="usd"/>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f408" decimals="0" contextRef="c6" unitRef="usd">67882.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:ProfitLoss id="f409" decimals="0" contextRef="c9" unitRef="usd">1756154.0</us-gaap:ProfitLoss>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="f410" contextRef="c5">&lt;p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zW1kiKzXLeCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zxG4DQ76lPT6"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
is generated by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access
to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on
a monthly-basis or task-basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration
of training and consulting projects are typically a few weeks or months and last no longer than 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SaaS-based
subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and
revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element
arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units
of accounting which are delivered items that have value to a customer on a standalone basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (ASU) 2014-09, Revenue
from Contracts with Customers (Topic 606), using the modified retrospective method. The modified retrospective adoption used by
the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially
all the Companys contracts with customers continues to be recognized over time as performance obligations are satisfied. &lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription
revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services.
The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identifying
                                            the contract with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identifying
                                            the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Determining
                                            the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Allocating
                                            the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues
from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the
Companys performance obligations and recognized over the period in which the performance obligations are satisfied. The Company
completes its contractual performance obligations through providing its customers access to specified data through subscriptions for
a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly
basis and does not provide any refunds, rights of return, or warranties to its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHAs
performance obligation is to manage ACO participants who provide healthcare services to CMSs members for the purpose of generating
shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared
savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS
into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment
factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be
fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment
within ten months after the fiscal year-end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHP
negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The Independent
Physicians Association (IPA) recognizes capitation payments received in advance from third-party insurers as revenue on
a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f411" decimals="INF" contextRef="c122" unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f412" decimals="INF" contextRef="c123" unitRef="shares">25188.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f413" decimals="INF" contextRef="c124" unitRef="shares">157143.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <clinigence.com:CommonStockIssuedForRelatedPartyNote id="f414" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f415" decimals="INF" contextRef="c125" unitRef="shares">5282545.0</us-gaap:SharesOutstanding>
  <us-gaap:NotesPayableCurrent id="f416" decimals="0" contextRef="c6" unitRef="usd">813127.0</us-gaap:NotesPayableCurrent>
  <clinigence.com:SellingAndMarketingExpenses id="f417" decimals="0" contextRef="c5" unitRef="usd">21154.0</clinigence.com:SellingAndMarketingExpenses>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f418" contextRef="c126">2019-09-06</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f419" contextRef="c127">2021-08-06</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f420" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f421" decimals="0" contextRef="c125" unitRef="usd">5282.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f422" decimals="INF" contextRef="c122" unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f423" decimals="INF" contextRef="c123" unitRef="shares">25188.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f424" decimals="INF" contextRef="c124" unitRef="shares">157143.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f425" decimals="0" contextRef="c128" unitRef="usd">17079885.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f426" decimals="INF" contextRef="c122" unitRef="usd1">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f427" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <us-gaap:ConvertibleDebtCurrent id="f428" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:ConvertibleDebtCurrent>
  <clinigence.com:SellingAndMarketingExpenses id="f429" decimals="0" contextRef="c9" unitRef="usd">-5248.0</clinigence.com:SellingAndMarketingExpenses>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f430" xsi:nil="true" contextRef="c130" unitRef="usd"/>
  <clinigence.com:IssuedDate id="f431" contextRef="c131">2021-01-28</clinigence.com:IssuedDate>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f432" decimals="0" contextRef="c132" unitRef="usd">-11708065.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdvertisingExpense id="f433" decimals="0" contextRef="c12" unitRef="usd">41418.0</us-gaap:AdvertisingExpense>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f434" decimals="INF" contextRef="c123" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f435" decimals="INF" contextRef="c124" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f436" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:LiabilitiesCurrent id="f437" decimals="0" contextRef="c6" unitRef="usd">6534518.0</us-gaap:LiabilitiesCurrent>
  <clinigence.com:OptionsOutstandingExpirationDate id="f438" contextRef="c120">2031-01-28</clinigence.com:OptionsOutstandingExpirationDate>
  <clinigence.com:SellingAndMarketingExpenses id="f439" decimals="0" contextRef="c12" unitRef="usd">168601.0</clinigence.com:SellingAndMarketingExpenses>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f440" decimals="0" contextRef="c55" unitRef="usd">5377102.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <clinigence.com:ExpirationDate id="f441" contextRef="c126">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f442" contextRef="c127">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:CapitalizedComputerSoftwareGross id="f443" decimals="0" contextRef="c6" unitRef="usd">41065.0</us-gaap:CapitalizedComputerSoftwareGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f444" decimals="INF" contextRef="c134" unitRef="shares">225000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f445" decimals="0" contextRef="c5" unitRef="usd">9074547.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f446" decimals="INF" contextRef="c135" unitRef="shares">1500.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f447" decimals="INF" contextRef="c136" unitRef="shares">128143.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <clinigence.com:CommonStockIssuedForRelatedPartyNote id="f448" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <us-gaap:NotesPayableCurrent id="f449" decimals="0" contextRef="c37" unitRef="usd">312890.0</us-gaap:NotesPayableCurrent>
  <us-gaap:GeneralAndAdministrativeExpense id="f450" decimals="0" contextRef="c1" unitRef="usd">1743089.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f451" contextRef="c137">2019-10-29</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f452" contextRef="c138">2021-08-11</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:OtherNoncashIncomeExpense id="f453" decimals="0" contextRef="c5" unitRef="usd">-24372.0</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f454" decimals="INF" contextRef="c134" unitRef="shares">225000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:LongTermNotesPayable id="f455" decimals="0" contextRef="c6" unitRef="usd">300000.0</us-gaap:LongTermNotesPayable>
  <us-gaap:GeneralAndAdministrativeExpense id="f456" decimals="0" contextRef="c5" unitRef="usd">7950353.0</us-gaap:GeneralAndAdministrativeExpense>
  <clinigence.com:LossOnExtinguishmentOfDebt id="f457" decimals="0" contextRef="c5" unitRef="usd">0.0</clinigence.com:LossOnExtinguishmentOfDebt>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="f458" contextRef="c5">&lt;p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zvvqNdyq8WWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
4  &lt;span id="xdx_824_zPy3fzx3Bmul"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are carried at cost and consist of the following at September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDo6sAtFQYv7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zuJyNZV43MF" style="display: none"&gt;Schedule of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49F_20210930_zYVb47slgCg3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_494_20201231_za3ogUK2q9W3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office equipment
    and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_zaIVF1I5sJ7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 12pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:
    Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(53,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(50,095&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: rgb(204,238,255)"&gt;Property, Plant and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,398&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,391&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation
expense of $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20210101__20210930_pp0p0" title="Depreciation expense"&gt;2,992&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--Depreciation_c20200101__20200930_pp0p0" title="Depreciation expense"&gt;13,376&lt;/span&gt; was charged to operations for the nine months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;







</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f459" decimals="INF" contextRef="c135" unitRef="shares">1500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f460" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="f461" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDo6sAtFQYv7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zuJyNZV43MF" style="display: none"&gt;Schedule of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49F_20210930_zYVb47slgCg3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_494_20201231_za3ogUK2q9W3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office equipment
    and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_zaIVF1I5sJ7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 12pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:
    Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(53,088&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(50,095&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: rgb(204,238,255)"&gt;Property, Plant and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,398&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,391&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f462" decimals="INF" contextRef="c134" unitRef="usd1">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f463" decimals="INF" contextRef="c136" unitRef="shares">128143.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f464" xsi:nil="true" contextRef="c79" unitRef="usd"/>
  <us-gaap:DepreciationDepletionAndAmortization id="f465" decimals="0" contextRef="c5" unitRef="usd">2993.0</us-gaap:DepreciationDepletionAndAmortization>
  <clinigence.com:IssuedDate id="f466" contextRef="c139">2021-02-25</clinigence.com:IssuedDate>
  <us-gaap:LiabilitiesCurrent id="f467" decimals="0" contextRef="c37" unitRef="usd">1153652.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:GeneralAndAdministrativeExpense id="f468" decimals="0" contextRef="c9" unitRef="usd">698598.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f469" decimals="0" contextRef="c5" unitRef="usd">-0.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f470" decimals="0" contextRef="c6" unitRef="usd">53088.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f471" decimals="INF" contextRef="c135" unitRef="usd1">25.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f472" xsi:nil="true" contextRef="c140" unitRef="usd"/>
  <clinigence.com:OptionsOutstandingExpirationDate id="f473" contextRef="c131">2028-01-28</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f474" decimals="INF" contextRef="c136" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet id="f475" decimals="0" contextRef="c6" unitRef="usd">2429500.0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <clinigence.com:ExpirationDate id="f476" contextRef="c137">February
                                            5, 2023</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f477" contextRef="c138">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="f478" decimals="0" contextRef="c12" unitRef="usd">-860730.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:FurnitureAndFixturesGross id="f479" decimals="0" contextRef="c6" unitRef="usd">5300.0</us-gaap:FurnitureAndFixturesGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f480" decimals="INF" contextRef="c141" unitRef="shares">290617.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f481" decimals="INF" contextRef="c142" unitRef="shares">1500.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f482" decimals="INF" contextRef="c143" unitRef="shares">42857.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f483" xsi:nil="true" contextRef="c144" unitRef="usd"/>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f484" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="f485" decimals="0" contextRef="c5" unitRef="usd">9074547.0</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f486" contextRef="c145">2019-10-29</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f487" contextRef="c146">2021-08-12</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:GeneralAndAdministrativeExpense id="f488" decimals="0" contextRef="c12" unitRef="usd">2876351.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f489" decimals="INF" contextRef="c141" unitRef="shares">290617.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f490" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f491" decimals="0" contextRef="c12" unitRef="usd">39752.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:CapitalizedComputerSoftwareNet id="f492" decimals="0" contextRef="c6" unitRef="usd">16121.0</us-gaap:CapitalizedComputerSoftwareNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f493" decimals="INF" contextRef="c142" unitRef="shares">1500.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f494" decimals="INF" contextRef="c143" unitRef="shares">42857.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f495" decimals="INF" contextRef="c141" unitRef="usd1">2.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:InterestAndDebtExpense id="f496" decimals="0" contextRef="c5" unitRef="usd">3315950.0</us-gaap:InterestAndDebtExpense>
  <us-gaap:GainsLossesOnSalesOfAssets id="f497" decimals="0" contextRef="c1" unitRef="usd">-0.0</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:CapitalizedComputerSoftwareGross id="f498" decimals="0" contextRef="c37" unitRef="usd">41065.0</us-gaap:CapitalizedComputerSoftwareGross>
  <clinigence.com:IssuedDate id="f499" contextRef="c147">2021-02-25</clinigence.com:IssuedDate>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f500" xsi:nil="true" contextRef="c140" unitRef="usd"/>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet id="f501" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f502" decimals="INF" contextRef="c142" unitRef="usd1">25.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f503" decimals="INF" contextRef="c143" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:GainsLossesOnSalesOfAssets id="f504" decimals="0" contextRef="c5" unitRef="usd">-0.0</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="f505" decimals="0" contextRef="c12" unitRef="usd">-820978.0</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <clinigence.com:OptionsOutstandingExpirationDate id="f506" contextRef="c139">2025-03-15</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:DepreciationAndAmortization id="f507" decimals="0" contextRef="c5" unitRef="usd">469435.0</us-gaap:DepreciationAndAmortization>
  <clinigence.com:ExpirationDate id="f508" contextRef="c145">April
                                            27, 2023</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f509" contextRef="c146">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f510" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f511" decimals="INF" contextRef="c148" unitRef="shares">200000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f512" decimals="INF" contextRef="c149" unitRef="shares">1666573.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f513" decimals="INF" contextRef="c150" unitRef="shares">14286.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:Liabilities id="f514" decimals="0" contextRef="c6" unitRef="usd">9331900.0</us-gaap:Liabilities>
  <us-gaap:GainsLossesOnSalesOfAssets id="f515" decimals="0" contextRef="c9" unitRef="usd">2404066.0</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:DepreciationDepletionAndAmortization id="f516" decimals="0" contextRef="c12" unitRef="usd">13376.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f517" contextRef="c151">2021-02-25</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f518" contextRef="c152">2021-08-17</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f519" decimals="INF" contextRef="c148" unitRef="shares">200000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CapitalizedComputerSoftwareNet id="f520" decimals="0" contextRef="c37" unitRef="usd">16121.0</us-gaap:CapitalizedComputerSoftwareNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f521" decimals="INF" contextRef="c149" unitRef="shares">1666573.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f522" decimals="INF" contextRef="c150" unitRef="shares">14286.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:CommonStockSubscribed id="f523" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f524" decimals="INF" contextRef="c148" unitRef="usd1">2.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <clinigence.com:DebtDiscountOnNotesPayable id="f525" xsi:nil="true" contextRef="c79" unitRef="usd"/>
  <us-gaap:LongTermNotesPayable id="f526" decimals="0" contextRef="c37" unitRef="usd">150000.0</us-gaap:LongTermNotesPayable>
  <us-gaap:DepreciationAndAmortization id="f527" decimals="0" contextRef="c12" unitRef="usd">94761.0</us-gaap:DepreciationAndAmortization>
  <clinigence.com:IssuedDate id="f528" contextRef="c154">2021-08-16</clinigence.com:IssuedDate>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f529" decimals="INF" contextRef="c6" unitRef="usd1">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:GainsLossesOnSalesOfAssets id="f530" decimals="0" contextRef="c12" unitRef="usd">4732244.0</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f531" decimals="INF" contextRef="c149" unitRef="usd1">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f532" decimals="INF" contextRef="c150" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f533" xsi:nil="true" contextRef="c140" unitRef="usd"/>
  <us-gaap:Depreciation id="f534" decimals="0" contextRef="c5" unitRef="usd">2992.0</us-gaap:Depreciation>
  <clinigence.com:OptionsOutstandingExpirationDate id="f535" contextRef="c147">2031-02-25</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:PreferredStockValue id="f536" decimals="0" contextRef="c6" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <clinigence.com:ExpirationDate id="f537" contextRef="c151">October
                                            31, 2025</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f538" contextRef="c152">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:PurchasePriceAdjustmentToInvestmentInAhp id="f539" decimals="0" contextRef="c5" unitRef="usd">300000.0</clinigence.com:PurchasePriceAdjustmentToInvestmentInAhp>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="f540" decimals="INF" contextRef="c155" unitRef="shares">75000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <clinigence.com:DebtDiscountOnNotesPayable id="f541" xsi:nil="true" contextRef="c140" unitRef="usd"/>
  <us-gaap:AdjustmentForAmortization id="f542" decimals="0" contextRef="c1" unitRef="usd">192131.0</us-gaap:AdjustmentForAmortization>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f543" decimals="INF" contextRef="c156" unitRef="shares">500000.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f544" decimals="INF" contextRef="c157" unitRef="shares">28571.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:Liabilities id="f545" decimals="0" contextRef="c37" unitRef="usd">1303652.0</us-gaap:Liabilities>
  <us-gaap:AdjustmentForAmortization id="f546" decimals="0" contextRef="c5" unitRef="usd">448306.0</us-gaap:AdjustmentForAmortization>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f547" decimals="0" contextRef="c37" unitRef="usd">50095.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f548" contextRef="c158">2021-02-25</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f549" contextRef="c159">2021-08-27</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f550" decimals="INF" contextRef="c155" unitRef="shares">75000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <clinigence.com:DebtDiscountOnNotesPayable id="f551" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:PreferredStockSharesAuthorized id="f552" decimals="INF" contextRef="c6" unitRef="shares">100000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:InterestAndDebtExpense id="f553" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:InterestAndDebtExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f554" decimals="INF" contextRef="c156" unitRef="shares">500000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f555" decimals="INF" contextRef="c157" unitRef="shares">28571.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="f556" decimals="INF" contextRef="c155" unitRef="usd1">2.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:AdjustmentForAmortization id="f557" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:AdjustmentForAmortization>
  <clinigence.com:GainsLossesOnSalesOfAssets1 id="f558" decimals="0" contextRef="c5" unitRef="usd">-0.0</clinigence.com:GainsLossesOnSalesOfAssets1>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f559" decimals="INF" contextRef="c37" unitRef="usd1">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="f560" contextRef="c5">&lt;p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4elnx34Tyo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
5  &lt;span id="xdx_828_zCoGxHv1hvVa"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following tables provide detail associated with the Companys acquired identifiable intangible assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z3CKgMsvGvTk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_z2YRpVOl0Je4" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Gross
                                            Carrying&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
                                            Carrying&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Useful
                                            Life&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(in
                                            years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,444,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(250,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,193,400&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0TLbxBupLQ" title="Intangible assets useful life"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;545,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(52,986&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;492,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0HxqOpP7Kwj" title="Intangible assets useful life"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PHP technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,729,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(144,720&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,584,280&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_zn49xAVT9ZMf" title="Intangible assets useful life"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,718,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(448,306&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,269,694&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zlLF5LfzADL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate
Amortization Expense:   &lt;b&gt;&lt;/b&gt;  &lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zj31SJ1CEL18" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Intangible Assets (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_z7GA43oo4DLb" style="display: none"&gt;Schedule of future amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Amortization Expense"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
                                            the nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AdjustmentForAmortization_c20210101__20210930_zL2U6PEksw2j" style="width: 43%; text-align: right" title="Amortization Expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;448,306&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_zyURxwplXWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f561" decimals="INF" contextRef="c156" unitRef="usd1">4.0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f562" decimals="INF" contextRef="c157" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:OptionsOutstandingExpirationDate id="f563" contextRef="c154">2027-08-16</clinigence.com:OptionsOutstandingExpirationDate>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f564" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:OtherNoncashIncomeExpense id="f565" decimals="0" contextRef="c12" unitRef="usd">-474344.0</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock id="f566" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z3CKgMsvGvTk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_z2YRpVOl0Je4" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Gross
                                            Carrying&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Net
                                            Carrying&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Useful
                                            Life&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(in
                                            years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,444,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(250,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="width: 10%; font-size: 12pt; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,193,400&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0TLbxBupLQ" title="Intangible assets useful life"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;545,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(52,986&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pp0p0" style="text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;492,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0HxqOpP7Kwj" title="Intangible assets useful life"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PHP technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,729,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(144,720&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,584,280&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_zn49xAVT9ZMf" title="Intangible assets useful life"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Intangible Assets, Gross"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,718,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Less: Accumulated amortization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(448,306&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210930_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Intangible Assets, Net"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9,269,694&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
  <clinigence.com:ExpirationDate id="f567" contextRef="c158">February
                                            26, 2026</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f568" contextRef="c159">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="f569" decimals="INF" contextRef="c6" unitRef="shares">2965431.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f570" xsi:nil="true" contextRef="c160" unitRef="usd"/>
  <us-gaap:PreferredStockSharesAuthorized id="f571" decimals="INF" contextRef="c37" unitRef="shares">100000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f572" decimals="INF" contextRef="c161" unitRef="shares">1506452.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f573" decimals="INF" contextRef="c162" unitRef="shares">71429.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:AdjustmentForAmortization id="f574" decimals="0" contextRef="c12" unitRef="usd">222032.0</us-gaap:AdjustmentForAmortization>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f575" decimals="0" contextRef="c5" unitRef="usd">144751.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f576" contextRef="c163">2021-02-25</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f577" contextRef="c164">2021-08-31</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f578" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:Depreciation id="f579" decimals="0" contextRef="c12" unitRef="usd">13376.0</us-gaap:Depreciation>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="f580" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z5s7XNE66bm1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zZG0ybRiUG3a" style="display: none"&gt;Schedule of Warrants, Activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/p&gt; &lt;p style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average &lt;span style="text-decoration: none"&gt;ExercisePrice&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual &lt;span style="text-decoration: none"&gt;Life (Years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding at December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200930_zQsDvdyn5EI5" style="width: 11%; text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,065,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;&lt;td style="width: 5%; font-size: 12pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200930_zJbAtvmSy1c" style="width: 11%; font-size: 12pt; text-align: right" title="Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231_znHpjs5lmy12" title="Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life"&gt;5.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsCancelled_iN_di_c20200101__20200930_zmsa00d6Q3Ck" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(507,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsCancelledPershare_d0_c20200101__20200930_zwPUB0KMDmaj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding
    at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200930_z8G8hpVVS9p2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200930_zCIfF3To0V65" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930_z9cJaMFE8wdi"&gt;4.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210930_zNDT8rS7RRll" style="text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;557,873&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zoatgvQd3LL4" style="text-align: right" title="Warrants, Outstanding, Beginning Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zOmf6pmNvam3" title="Warrants, Outstanding, Beginning Balance"&gt;3.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsNoWarrantGranted_c20210101__20210930_zBmEenLWJSC1" style="text-align: right" title="Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,648,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsNoWarrantActivityWeightedAverageGranted_c20210101__20210930_zzpbcsLzDmQh" style="text-align: right" title="Warrant Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsNoWarrantExercised_iN_di_c20210101__20210930_zxcMun3rNWG5" style="text-align: right" title="Warrant Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(48,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantsNoWarrantActivityWeightedAverageExercisePrice_c20210101__20210930_zUq2JatO6cle" style="text-align: right" title="Warrants exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants
    assumed in merger&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,415,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsAssumedInMergerWarrantsAssumedInMerger_c20210101__20210930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, assumed in merger, Warrants, assumed in merger"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding
    at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210930_zNNnl8w4fptf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210930_zuZ4W6cJFo2c" style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right" title="Warrants, Outstanding, Ending Balance"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210930_zGeVzvUbkfGe" title="Warrants, Outstanding, Ending Balance"&gt;5.31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:GainLossOnDispositionOfAssets id="f581" decimals="0" contextRef="c5" unitRef="usd">-0.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="f582" decimals="0" contextRef="c98" unitRef="usd">6444000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f583" decimals="INF" contextRef="c161" unitRef="shares">1506452.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f584" decimals="INF" contextRef="c162" unitRef="shares">71429.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:PreferredStockSharesOutstanding id="f585" decimals="INF" contextRef="c37" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f586" xsi:nil="true" contextRef="c166" unitRef="usd"/>
  <us-gaap:OperatingExpenses id="f587" decimals="0" contextRef="c12" unitRef="usd">-962299.0</us-gaap:OperatingExpenses>
  <us-gaap:PreferredStockSharesOutstanding id="f588" decimals="INF" contextRef="c6" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="f589" decimals="0" contextRef="c98" unitRef="usd">6193400.0</us-gaap:FiniteLivedIntangibleAssetsNet>
  <clinigence.com:GainsLossesOnSalesOfAssets1 id="f590" decimals="0" contextRef="c12" unitRef="usd">4732244.0</clinigence.com:GainsLossesOnSalesOfAssets1>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="f591" decimals="0" contextRef="c167" unitRef="usd">-144720.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f592" decimals="INF" contextRef="c161" unitRef="usd1">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f593" decimals="INF" contextRef="c162" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f594" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:OperatingExpenses id="f595" decimals="0" contextRef="c5" unitRef="usd">8628428.0</us-gaap:OperatingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="f596" contextRef="c12">P4Y14D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <clinigence.com:ExpirationDate id="f597" contextRef="c163">February
                                            1, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f598" contextRef="c164">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f599" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:PreferredStockSharesIssued id="f600" decimals="INF" contextRef="c37" unitRef="shares">0.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f601" decimals="INF" contextRef="c168" unitRef="shares">2694190.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f602" decimals="INF" contextRef="c169" unitRef="shares">228572.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="f603" decimals="0" contextRef="c98" unitRef="usd">-250600.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:OperatingExpenses id="f604" decimals="0" contextRef="c9" unitRef="usd">-1636889.0</us-gaap:OperatingExpenses>
  <us-gaap:GainLossOnDispositionOfAssets id="f605" decimals="0" contextRef="c12" unitRef="usd">-1621.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f606" decimals="INF" contextRef="c43" unitRef="shares">1065251.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f607" contextRef="c170">2021-02-25</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f608" contextRef="c171">2021-09-01</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="f609" decimals="0" contextRef="c91" unitRef="usd">545000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f610" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:OperatingIncomeLoss id="f611" decimals="0" contextRef="c1" unitRef="usd">-824111.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f612" decimals="INF" contextRef="c168" unitRef="shares">2694190.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f613" decimals="INF" contextRef="c169" unitRef="shares">228572.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice id="f614" decimals="INF" contextRef="c43" unitRef="usd1">6.04</clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f615" decimals="INF" contextRef="c37" unitRef="shares">557873.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f616" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f617" decimals="INF" contextRef="c6" unitRef="usd1">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="f618" decimals="0" contextRef="c91" unitRef="usd">-52986.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f619" decimals="INF" contextRef="c168" unitRef="usd1">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f620" decimals="INF" contextRef="c169" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:OperatingIncomeLoss id="f621" decimals="0" contextRef="c12" unitRef="usd">1481668.0</us-gaap:OperatingIncomeLoss>
  <clinigence.com:CancellationOfCommonStock id="f622" decimals="0" contextRef="c5" unitRef="usd">-0.0</clinigence.com:CancellationOfCommonStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="f623" contextRef="c45">P5Y2M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <clinigence.com:ExpirationDate id="f624" contextRef="c170">July
                                            31, 2026</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f625" contextRef="c171">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="f626" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:CommonStockSharesIssued id="f627" decimals="INF" contextRef="c6" unitRef="shares">45595316.0</us-gaap:CommonStockSharesIssued>
  <clinigence.com:WarrantsCancelled id="f628" decimals="INF" contextRef="c12" unitRef="shares">507378.0</clinigence.com:WarrantsCancelled>
  <us-gaap:OperatingIncomeLoss id="f629" decimals="0" contextRef="c5" unitRef="usd">-5910908.0</us-gaap:OperatingIncomeLoss>
  <clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice id="f630" decimals="INF" contextRef="c37" unitRef="usd1">6.77</clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f631" decimals="INF" contextRef="c172" unitRef="shares">651429.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f632" decimals="INF" contextRef="c173" unitRef="shares">50000.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <clinigence.com:CommonStockSubscribed id="f633" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <clinigence.com:LossOnExtinguishmentOfDebt id="f634" decimals="0" contextRef="c12" unitRef="usd">167797.0</clinigence.com:LossOnExtinguishmentOfDebt>
  <clinigence.com:WarrantsCancelledPershare id="f635" decimals="INF" contextRef="c12" unitRef="usd1">0.0</clinigence.com:WarrantsCancelledPershare>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f636" contextRef="c174">2021-05-14</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f637" contextRef="c175">2021-09-03</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:PreferredStockValue id="f638" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <us-gaap:OperatingIncomeLoss id="f639" decimals="0" contextRef="c9" unitRef="usd">1776027.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="f640" decimals="0" contextRef="c91" unitRef="usd">492014.0</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f641" decimals="INF" contextRef="c55" unitRef="shares">557873.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f642" decimals="INF" contextRef="c172" unitRef="shares">651429.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f643" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:CommonStockSharesOutstanding id="f644" decimals="INF" contextRef="c37" unitRef="shares">5282545.0</us-gaap:CommonStockSharesOutstanding>
  <clinigence.com:IncomeLossFromEarningsFromEquityInvestment id="f645" decimals="0" contextRef="c1" unitRef="usd">583981.0</clinigence.com:IncomeLossFromEarningsFromEquityInvestment>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f646" decimals="INF" contextRef="c173" unitRef="shares">50000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f647" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f648" decimals="INF" contextRef="c6" unitRef="shares">800000000.0</us-gaap:CommonStockSharesAuthorized>
  <clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice id="f649" decimals="INF" contextRef="c55" unitRef="usd1">6.77</clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice>
  <us-gaap:GainOrLossOnSaleOfStockInSubsidiary id="f650" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f651" decimals="INF" contextRef="c172" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f652" decimals="INF" contextRef="c173" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition id="f653" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:GainOrLossOnSaleOfStockInSubsidiary id="f654" decimals="0" contextRef="c12" unitRef="usd">-158744.0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="f655" contextRef="c48">P3Y9M14D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f656" decimals="INF" contextRef="c37" unitRef="usd1">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="f657" decimals="0" contextRef="c167" unitRef="usd">2729000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <clinigence.com:ExpirationDate id="f658" contextRef="c174">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f659" contextRef="c175">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:CancellationOfCommonStock id="f660" decimals="0" contextRef="c12" unitRef="usd">33750.0</clinigence.com:CancellationOfCommonStock>
  <clinigence.com:WarrantsNoWarrantActivityWeightedAverageGranted id="f661" decimals="INF" contextRef="c5" unitRef="usd1">1.94</clinigence.com:WarrantsNoWarrantActivityWeightedAverageGranted>
  <us-gaap:GainOrLossOnSaleOfStockInSubsidiary id="f662" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f663" decimals="INF" contextRef="c176" unitRef="shares">228571.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f664" decimals="INF" contextRef="c177" unitRef="shares">88571.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="f665" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="f666" decimals="0" contextRef="c6" unitRef="usd">-448306.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <clinigence.com:WarrantsNoWarrantGranted id="f667" decimals="INF" contextRef="c5" unitRef="shares">4648143.0</clinigence.com:WarrantsNoWarrantGranted>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f668" contextRef="c178">2021-05-28</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f669" contextRef="c179">2021-09-09</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f670" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <us-gaap:GainOrLossOnSaleOfStockInSubsidiary id="f671" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
  <us-gaap:IncreaseDecreaseInDeposits id="f672" decimals="0" contextRef="c5" unitRef="usd">410.0</us-gaap:IncreaseDecreaseInDeposits>
  <clinigence.com:IncomeFromForgivenessOfDebts id="f673" decimals="0" contextRef="c5" unitRef="usd">311125.0</clinigence.com:IncomeFromForgivenessOfDebts>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="f674" decimals="0" contextRef="c167" unitRef="usd">2584280.0</us-gaap:FiniteLivedIntangibleAssetsNet>
  <clinigence.com:WarrantsNoWarrantExercised id="f675" decimals="INF" contextRef="c5" unitRef="shares">48750.0</clinigence.com:WarrantsNoWarrantExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f676" decimals="INF" contextRef="c176" unitRef="shares">228571.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f677" decimals="INF" contextRef="c177" unitRef="shares">88571.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f678" xsi:nil="true" contextRef="c153" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f679" decimals="INF" contextRef="c37" unitRef="shares">800000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensation id="f680" decimals="0" contextRef="c5" unitRef="usd">4026884.0</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f681" xsi:nil="true" contextRef="c166" unitRef="usd"/>
  <clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice id="f682" decimals="INF" contextRef="c6" unitRef="usd1">2.06</clinigence.com:WarrantsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f683" decimals="INF" contextRef="c176" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f684" decimals="INF" contextRef="c177" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition id="f685" xsi:nil="true" contextRef="c165" unitRef="usd"/>
  <clinigence.com:IncomeFromForgivenessOfDebt id="f686" decimals="0" contextRef="c1" unitRef="usd">0.0</clinigence.com:IncomeFromForgivenessOfDebt>
  <us-gaap:CommonStockSharesOutstanding id="f687" decimals="INF" contextRef="c6" unitRef="shares">45595316.0</us-gaap:CommonStockSharesOutstanding>
  <clinigence.com:IncomeFromForgivenessOfDebt id="f688" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:IncomeFromForgivenessOfDebt>
  <clinigence.com:PurchasePriceAdjustmentToInvestmentInAhp id="f689" decimals="0" contextRef="c12" unitRef="usd">-0.0</clinigence.com:PurchasePriceAdjustmentToInvestmentInAhp>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="f690" decimals="0" contextRef="c6" unitRef="usd">9718000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
  <clinigence.com:ExpirationDate id="f691" contextRef="c178">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f692" xsi:nil="true" contextRef="c180" unitRef="usd"/>
  <clinigence.com:ExpirationDate id="f693" contextRef="c179">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="f694" contextRef="c5">P5Y3M21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f695" decimals="INF" contextRef="c181" unitRef="shares">182857.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f696" decimals="INF" contextRef="c182" unitRef="shares">14286.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f697" xsi:nil="true" contextRef="c183" unitRef="usd"/>
  <clinigence.com:IncomeFromEarningsFromEquityInvestment id="f698" decimals="0" contextRef="c5" unitRef="usd">444171.0</clinigence.com:IncomeFromEarningsFromEquityInvestment>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock id="f699" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zj31SJ1CEL18" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Intangible Assets (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_z7GA43oo4DLb" style="display: none"&gt;Schedule of future amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Amortization Expense"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
                                            the nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AdjustmentForAmortization_c20210101__20210930_zL2U6PEksw2j" style="width: 43%; text-align: right" title="Amortization Expense"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;448,306&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f700" contextRef="c184">2021-06-11</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f701" contextRef="c185">2021-09-17</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f702" xsi:nil="true" contextRef="c186" unitRef="usd"/>
  <us-gaap:CommonStockSharesIssued id="f703" decimals="INF" contextRef="c37" unitRef="shares">5282545.0</us-gaap:CommonStockSharesIssued>
  <clinigence.com:IncomeFromForgivenessOfDebt id="f704" decimals="0" contextRef="c5" unitRef="usd">314807.0</clinigence.com:IncomeFromForgivenessOfDebt>
  <clinigence.com:WarrantsNoWarrantActivityWeightedAverageExercisePrice id="f705" decimals="INF" contextRef="c5" unitRef="usd1">1.25</clinigence.com:WarrantsNoWarrantActivityWeightedAverageExercisePrice>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="f706" decimals="0" contextRef="c6" unitRef="usd">9269694.0</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f707" decimals="INF" contextRef="c181" unitRef="shares">182857.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f708" decimals="INF" contextRef="c182" unitRef="shares">14286.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f709" xsi:nil="true" contextRef="c187" unitRef="usd"/>
  <clinigence.com:IncomeFromForgivenessOfDebts id="f710" decimals="0" contextRef="c12" unitRef="usd">-0.0</clinigence.com:IncomeFromForgivenessOfDebts>
  <us-gaap:CommonStockValue id="f711" decimals="0" contextRef="c6" unitRef="usd">45595.0</us-gaap:CommonStockValue>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f712" xsi:nil="true" contextRef="c188" unitRef="usd"/>
  <clinigence.com:IncomeFromForgivenessOfDebt id="f713" decimals="0" contextRef="c9" unitRef="usd">0.0</clinigence.com:IncomeFromForgivenessOfDebt>
  <us-gaap:OtherOwnershipInterestsValue id="f714" decimals="0" contextRef="c189" unitRef="usd">7134000.0</us-gaap:OtherOwnershipInterestsValue>
  <clinigence.com:ScheduleOfOutstandingWarrantsTableTextBlock id="f715" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_z8GZwlQcc1Mf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Based Compensation (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="vertical-align: bottom; text-align: left"&gt;&lt;span id="xdx_8BF_zzN2NNnG4xY4" style="display: none"&gt;Schedule of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 1%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 16%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_zELz2oXEJMR4" title="Issued Date"&gt;March
                                            21, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 16%; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;96,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 16%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;96,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member_pdd" style="width: 15%; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants1Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_z1jVtd9WUl51" title="Issued Date"&gt;April
                                            30, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,598&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants2Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_zDQjKN9f682g" title="Issued Date"&gt;May
                                            13, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,393&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,393&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants3Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_zvjV08w5zBq1" title="Issued Date"&gt;May
                                            28, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;199,703&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;199,703&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants4Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_zzd4k4J3KdY1" title="Issued Date"&gt;June
                                            5, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants5Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_zQHGzhK1Eoca" title="Issued Date"&gt;June
                                            25, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;208,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants6Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_zJj2gDfLHePl" title="Issued Date"&gt;September
                                            6, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants7Member" title="Expiration Date"&gt;December
                                            31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_zsVzUYSE2xl1" title="Issued Date"&gt;October
                                            29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants8Member" title="Expiration Date"&gt;February
                                            5, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_zQtgY4gaNpuf" title="Issued Date"&gt;October
                                            29, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;25.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants9Member" title="Expiration Date"&gt;April
                                            27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_zJ28QkrMCCF9" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,666,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,666,573&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants10Member" title="Expiration Date"&gt;October
                                            31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_zNHRQcIvVhu8" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants11Member" title="Expiration Date"&gt;February
                                            26, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_z4uceQhGqROe" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,506,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,506,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants12Member" title="Expiration Date"&gt;February
                                            1, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_zmB4WO2lWJFe" title="Issued Date"&gt;February
                                            25, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,694,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,694,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants13Member" title="Expiration Date"&gt;July
                                            31, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_z1KV3cOf6nr3" title="Issued Date"&gt;May
                                            14, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;651,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;651,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants14Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_z61JfMDuX3H4" title="Issued Date"&gt;May
                                            28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants15Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_zq7eH6ZjeCni" title="Issued Date"&gt;June
                                            11, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;182,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;182,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants16Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_zoyzRiTrnwfe" title="Issued Date"&gt;June
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;137,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;137,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants17Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_zGbyVRnQ72z6" title="Issued Date"&gt;June
                                            24, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;169,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;169,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants18Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_z02wsKgo2wOc" title="Issued Date"&gt;June
                                            28, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants19Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_zLgnnVOJMaf5" title="Issued Date"&gt;June
                                            29, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants20Member" title="Expiration Date"&gt;May
                                            30, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_zcPtAlEI1CX7" title="Issued Date"&gt;July
                                            6, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member_pdd" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants21Member" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zEJ9QcqsVsc" title="Issued Date"&gt;July
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zulz3Tndmlqb" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_z4PbDAwHlMO4" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zqyhZHvRNJEg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants22Member_zU25jZ7i2cI8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zkRO0kqZqSt" title="Issued Date"&gt;July
                                            29, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zBMe7GhKGYbc" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zdSIsBAnWmYb" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zTyuLdmLb7l2" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants23Member_zg7rSS4PvNo1" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zefkye3kTnzh" title="Issued Date"&gt;August
                                            6, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_z6LpjqQ3XfJa" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zZbcAl89gSP9" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;157,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zV6Vq8PQgjJg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants24Member_zhxISoHMOar6" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zXT3FmRgkNF1" title="Issued Date"&gt;August
                                            11, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zAN9sq3nKxA" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;128,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zpZYGcP055Oi" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;128,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_z0IuvcD4uNR8" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants25Member_zvOEy6BoKYqe" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zen8kftpg5aj" title="Issued Date"&gt;August
                                            12, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_z8X4XP4TYySl" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;42,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zHsCuTfxCwBd" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;42,857&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zotz53PTaF3a" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants26Member_zsQA6Kal3TN8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_zFSNOOT60UId" title="Issued Date"&gt;August
                                            17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z2dxzGpQ5ayi" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z27SpNB6wAj9" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_zOtPToNjcE9c" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants27Member_z6j5cXY3BYq8" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zMal1PriB9ze" title="Issued Date"&gt;August
                                            27, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zhVN5zySgUyi" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_z1sEVDHnRFC7" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_zwnxnGJo5G9j" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants28Member_z5WsGnZR4qEg" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_z5cZsCscjjIj" title="Issued Date"&gt;August
                                            31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zUCDEnnlZQU6" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zkh5Lz3kFalh" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zRf06XxkhQci" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants29Member_zYIkPjLL70Z4" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zNBORZfrrMmk" title="Issued Date"&gt;September
                                            1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zWHSrbTcIxzc" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,572&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_z5iw4t4a9pk7" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;228,572&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zcAWqcG1Ffz3" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants30Member_zlHlUCWJezJ6" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zQz7zu0cFo3g" title="Issued Date"&gt;September
                                            3, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zPEARedZTWHh" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zRgEGmdOjRM4" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zwgfZQC3vC0c" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants31Member_zlFDl9Xgkyb3" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zg9KgDOWEqwa" title="Issued Date"&gt;September
                                            9, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zxsNXMRHJjib" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;88,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zdSBjOAsbsQ3" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;88,571&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_z74OJufwldI" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants32Member_zvpZgfah4ofa" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zLi66o4i62Zc" title="Issued Date"&gt;September
                                            17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zvUvEisJukP7" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zHX5CZ1nNP1d" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_zEJnCyUK9Z9l" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants33Member_znv9T40qRn88" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zXksOR8Mc8dl" title="Issued Date"&gt;September
                                            20, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zNkq411DWtV7" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_z8AaN630JEa2" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zNbDAEU6w1Sg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants34Member_zf9RwVrLBNyi" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zX1bD0tfB0Yd" title="Issued Date"&gt;September
                                            22, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zMcH8toiB0Bj" style="text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zNTzAAfHB0Kb" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zm7cozV18PQ4" style="text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants35Member_zJWOCQ2Qnkwe" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zb6Zl6jwvIIf" title="Issued Date"&gt;September
                                            23, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zkPt42WBYldj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zOT591qBXge2" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_zOd6kqiawoH5" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_ecustom--ExpirationDate_c20210101__20210930__us-gaap--AwardTypeAxis__custom--Warrants36Member_ziqMx1mdGe9i" title="Expiration Date"&gt;May
                                            31, 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20210930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,573,231&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:ScheduleOfOutstandingWarrantsTableTextBlock>
  <clinigence.com:OperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesTableTextBlock id="f716" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--OperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesTableTextBlock_zwNgGV1q0plf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zVQwu2ipTI7b" style="display: none"&gt;Schedule Operating lease ROU assets and operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20210930_zFERzzOZvdwh" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease
    right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;108,842&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current portion of operating
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liabilities,
    net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;67,882&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:OperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesTableTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f717" decimals="INF" contextRef="c181" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f718" decimals="INF" contextRef="c182" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f719" xsi:nil="true" contextRef="c190" unitRef="usd"/>
  <clinigence.com:IncomeFromEarningsFromEquityInvestment id="f720" decimals="0" contextRef="c12" unitRef="usd">-0.0</clinigence.com:IncomeFromEarningsFromEquityInvestment>
  <clinigence.com:ExpirationDate id="f721" contextRef="c184">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f722" contextRef="c185">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:ProfitLoss id="f723" xsi:nil="true" contextRef="c191" unitRef="usd"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f724" decimals="0" contextRef="c37" unitRef="usd">-1133795.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <clinigence.com:WarrantsAssumedInMerger id="f725" decimals="INF" contextRef="c5" unitRef="shares">6415965.0</clinigence.com:WarrantsAssumedInMerger>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f726" decimals="INF" contextRef="c192" unitRef="shares">137143.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f727" decimals="INF" contextRef="c193" unitRef="shares">422856.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f728" xsi:nil="true" contextRef="c187" unitRef="usd"/>
  <us-gaap:GainLossOnSaleOfOtherAssets id="f729" decimals="0" contextRef="c9" unitRef="usd">-1621.0</us-gaap:GainLossOnSaleOfOtherAssets>
  <clinigence.com:OptionsIssuedForServicesValue id="f730" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:AdditionalPaidInCapital id="f731" decimals="0" contextRef="c6" unitRef="usd">101187532.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="f732" decimals="0" contextRef="c5" unitRef="usd">253818.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f733" contextRef="c194">2021-06-22</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f734" contextRef="c195">2021-09-20</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f735" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:InvestmentTextBlock id="f736" contextRef="c5">&lt;p id="xdx_803_eus-gaap--InvestmentTextBlock_zFBOsly8Mcsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
6 &lt;span id="xdx_821_zGClxLsMela3"&gt; Investment in ACMG&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the acquisition of Accountable Care Medical Group of Florida, Inc. (ACMG), AHA defaulted on its payment
obligations of $&lt;span id="xdx_90E_eus-gaap--PaymentsToAcquireInvestments_c20210101__20210930__dei--LegalEntityAxis__custom--AHAMember_pp0p0" title="Payment obligations"&gt;15,000,000&lt;/span&gt; by the extended payment due date of November 15, 2020. Accordingly, AHA was required to return 71% of its
ownership to the shareholders of ACMG in full settlement of the default. Consequently, AHA deconsolidated its reporting of ACMG. The
Company recognized that AHA held a non-controlling 29% equity ownership interest in ACMG as of February 28, 2021 that was required to
be measured at fair value. The Company determined through the services of an independent valuation under ASC 805 using an income approach,
market approach, and asset-based approach that the fair value of its &lt;span id="xdx_903_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20210930__srt--OwnershipAxis__custom--ACMGMember_zUGL89mlGhf5" title="Non-controlling interest"&gt;29&lt;/span&gt;% equity ownership interest in ACMG is $&lt;span id="xdx_90A_eus-gaap--OtherOwnershipInterestsValue_c20210930__srt--OwnershipAxis__custom--ACMGMember_pp0p0" title="Ownership Interest"&gt;7,134,000&lt;/span&gt;. For the period
March 1, 2021 through September 30, 2021, the Company reported income from earnings from its investment in ACMG of $&lt;span id="xdx_90A_ecustom--InvestmentLoss_c20210930_pp0p0" title="Investment loss"&gt;444,171&lt;/span&gt;. Investment
in ACMG was $&lt;span id="xdx_907_ecustom--InvestmentLoss_c20210930__dei--LegalEntityAxis__custom--ACMGMember_pp0p0" title="Investment loss"&gt;7,578,171&lt;/span&gt; at September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
  <clinigence.com:WarrantsAssumedInMergerWarrantsAssumedInMerger id="f737" decimals="INF" contextRef="c5" unitRef="usd1">1.74</clinigence.com:WarrantsAssumedInMergerWarrantsAssumedInMerger>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f738" decimals="INF" contextRef="c192" unitRef="shares">137143.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f739" decimals="INF" contextRef="c193" unitRef="shares">422856.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:PaymentsToAcquireInvestments id="f740" decimals="0" contextRef="c196" unitRef="usd">15000000.0</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f741" xsi:nil="true" contextRef="c188" unitRef="usd"/>
  <us-gaap:ShareBasedCompensation id="f742" decimals="0" contextRef="c12" unitRef="usd">2571689.0</us-gaap:ShareBasedCompensation>
  <us-gaap:CommonStockValue id="f743" decimals="0" contextRef="c37" unitRef="usd">5282.0</us-gaap:CommonStockValue>
  <us-gaap:GainLossOnSaleOfOtherAssets id="f744" decimals="0" contextRef="c12" unitRef="usd">-1621.0</us-gaap:GainLossOnSaleOfOtherAssets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="f745" decimals="INF" contextRef="c6" unitRef="shares">11573231.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f746" decimals="0" contextRef="c6" unitRef="usd">-27305852.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:IncreaseDecreaseInCustomerDeposits id="f747" decimals="0" contextRef="c5" unitRef="usd">-13325.0</us-gaap:IncreaseDecreaseInCustomerDeposits>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f748" decimals="INF" contextRef="c192" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f749" decimals="INF" contextRef="c193" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f750" xsi:nil="true" contextRef="c197" unitRef="usd"/>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners id="f751" decimals="INF" contextRef="c189" unitRef="pure">0.29</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f752" decimals="INF" contextRef="c82" unitRef="shares">3598.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:ExpirationDate id="f753" contextRef="c194">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f754" contextRef="c195">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <us-gaap:MinorityInterest id="f755" decimals="0" contextRef="c6" unitRef="usd">12343.0</us-gaap:MinorityInterest>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f756" decimals="0" contextRef="c12" unitRef="usd">-17851.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f757" decimals="0" contextRef="c12" unitRef="usd">-167797.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:LesseeOperatingLeasesTextBlock id="f758" contextRef="c5">&lt;p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_z0UVR5lgdrr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
7  &lt;span id="xdx_822_z5uaEpJ2S9d9"&gt;Operating Lease&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determines if a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use
("ROU") assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the
Company's consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations
and finance lease obligations, net of current portion in the Company's unaudited consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ROU
assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease
payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value
of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease
payments made at or before the commencement date and exclude lease incentives. The Company used the implicit rate in the lease in determining
the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
terms include options to extend or terminatethe lease when it is reasonably certain that the Company will exercise that option.
Leases with a term of one year or less are generally not included in ROU assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheet as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--OperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesTableTextBlock_zwNgGV1q0plf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zVQwu2ipTI7b" style="display: none"&gt;Schedule Operating lease ROU assets and operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20210930_zFERzzOZvdwh" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease
    right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;108,842&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current portion of operating
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,440&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liabilities,
    net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;67,882&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2021, the weighted-average remaining lease term of the operating lease was &lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210930_zT7yq3Qv0KJ2" title="Operating Lease, Weighted Average Remaining Lease Term"&gt;2.3&lt;/span&gt; years. The weighted-average discount
rate for the operating lease was &lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210930_zFnrVQbuEG5h" title="Operating Lease, Weighted Average Discount Rate, Percent"&gt;6.75&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes maturities of operating lease liabilities based on lease term as of September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXKvnQ5bXILa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zDl8HCCORkNg" style="display: none"&gt;Schedule summarizes maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_490_20210930_zFphnNYPU0r7" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;51,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;53,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ReceivableWithImputedInterestNetAmount_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:
    Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,903&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present
    value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;113,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2021, the Company had the following future minimum payments due under the non-cancelable lease:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfFutureMinimumPaymentsDueUnderNoncancelableLeaseTableTextBlock_z8P0jGTezqFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zuoaQdiPsb89" style="display: none"&gt;Schedule minimum payments due under the non-cancelable lease&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_498_20210930_zm5qVuFacmV3" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;51,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;53,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0_zqEiVfOQSIlg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;122,225&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Consolidated
rental expense from continuing operations for all operating leases was $&lt;span id="xdx_906_eus-gaap--OperatingLeasesRentExpenseNet_c20210101__20210930__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pp0p0" title="Rental expense"&gt;68,497&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLeasesRentExpenseNet_c20200101__20200930__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pp0p0" title="Rental expense"&gt;82,374&lt;/span&gt; for the nine months ended September 30, 2021
and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the cash paid and related right-of-use operating lease recognized for the nine months ended September 30,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--LeaseCostTableTextBlock_z1PiD9r6KzN8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_z0GRzm50YZJ7" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease recognized&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20210101__20210930_zyo4pvsdnNni" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nine Months
    Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included
    in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating cash
    flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;37,688&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use lease assets
    obtained in the exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--OperatingLeases_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;16,649&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;








</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f759" decimals="INF" contextRef="c198" unitRef="shares">169143.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f760" decimals="INF" contextRef="c199" unitRef="shares">1328002.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <clinigence.com:OptionsIssuedForServicesValue id="f761" xsi:nil="true" contextRef="c200" unitRef="usd"/>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f762" contextRef="c201">2021-06-24</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f763" contextRef="c202">2021-09-22</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f764" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:AdditionalPaidInCapital id="f765" decimals="0" contextRef="c37" unitRef="usd">17079885.0</us-gaap:AdditionalPaidInCapital>
  <clinigence.com:IncomeLossFromEarningsFromEquityInvestment id="f766" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:IncomeLossFromEarningsFromEquityInvestment>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f767" contextRef="c203">2019-03-21</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="f768" decimals="0" contextRef="c5" unitRef="usd">-1445178.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f769" decimals="INF" contextRef="c198" unitRef="shares">169143.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f770" decimals="INF" contextRef="c199" unitRef="shares">1328002.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:IncomeLossFromEarningsFromEquityInvestment id="f771" decimals="0" contextRef="c5" unitRef="usd">444171.0</clinigence.com:IncomeLossFromEarningsFromEquityInvestment>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f772" decimals="INF" contextRef="c204" unitRef="shares">96433.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f773" contextRef="c85">2019-04-30</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f774" xsi:nil="true" contextRef="c205" unitRef="usd"/>
  <clinigence.com:InvestmentLoss id="f775" decimals="0" contextRef="c6" unitRef="usd">444171.0</clinigence.com:InvestmentLoss>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f776" decimals="0" contextRef="c37" unitRef="usd">-18218962.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="f777" decimals="0" contextRef="c12" unitRef="usd">86650.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f778" decimals="INF" contextRef="c198" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f779" decimals="INF" contextRef="c199" unitRef="usd1">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <clinigence.com:IncomeLossFromEarningsFromEquityInvestment id="f780" decimals="0" contextRef="c9" unitRef="usd">0.0</clinigence.com:IncomeLossFromEarningsFromEquityInvestment>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f781" decimals="INF" contextRef="c204" unitRef="shares">96433.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <clinigence.com:ExpirationDate id="f782" contextRef="c201">May
                                            30, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:ExpirationDate id="f783" contextRef="c202">May
                                            31, 2027</clinigence.com:ExpirationDate>
  <clinigence.com:OptionsIssuedForServicesValue id="f784" xsi:nil="true" contextRef="c206" unitRef="usd"/>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f785" decimals="INF" contextRef="c82" unitRef="shares">3598.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f786" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f787" decimals="INF" contextRef="c83" unitRef="shares">45714.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="f788" decimals="INF" contextRef="c2" unitRef="shares">500000.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f789" decimals="0" contextRef="c6" unitRef="usd">73939618.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncreaseDecreaseInDeposits id="f790" decimals="0" contextRef="c12" unitRef="usd">1240.0</us-gaap:IncreaseDecreaseInDeposits>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="f791" decimals="INF" contextRef="c204" unitRef="usd1">6.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f792" contextRef="c86">2021-06-28</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DebtInstrumentIssuanceDate1 id="f793" contextRef="c3">2021-09-23</us-gaap:DebtInstrumentIssuanceDate1>
  <clinigence.com:OptionsIssuedForServicesValue id="f794" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="f795" decimals="0" contextRef="c9" unitRef="usd">0.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f796" decimals="INF" contextRef="c2" unitRef="shares">500000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="f797" decimals="INF" contextRef="c83" unitRef="shares">45714.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="f798" decimals="0" contextRef="c12" unitRef="usd">-661379.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <clinigence.com:InvestmentLoss id="f799" decimals="0" contextRef="c207" unitRef="usd">7578171.0</clinigence.com:InvestmentLoss>
  <clinigence.com:ExpirationDate id="f800" contextRef="c203">December
                                            31, 2024</clinigence.com:ExpirationDate>
  <us-gaap:MinorityInterest id="f801" decimals="0" contextRef="c37" unitRef="usd">0.0</us-gaap:MinorityInterest>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f802" decimals="0" contextRef="c5" unitRef="usd">2793578.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f803" decimals="0" contextRef="c5" unitRef="usd">-16649.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <clinigence.com:ConvertedWarrants id="f804" decimals="0" contextRef="c5" unitRef="usd">1725000.0</clinigence.com:ConvertedWarrants>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f805" decimals="0" contextRef="c5" unitRef="usd">-3970719.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents id="f806" decimals="0" contextRef="c208" unitRef="usd">697191.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:DecreaseInRestrictedCash id="f807" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:DecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="f808" decimals="0" contextRef="c5" unitRef="usd">224466.0</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <clinigence.com:InvestorsForProceeds id="f809" decimals="0" contextRef="c209" unitRef="usd">1562.0</clinigence.com:InvestorsForProceeds>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock id="f810" contextRef="c5">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zXLhAS9yUvii" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
1 - &lt;span id="xdx_828_zMnBPl2mRSCj"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the Company)
and its wholly-owned subsidiaries, Accountable Healthcare America, Inc. (AHA), AHP Management, Inc. (AHP),
Clinigence Health, Inc. (Clinigence) and HealthDatix, Inc. (HealthDatix). The Companys name was changed
to Clinigence Holdings, Inc. on October 29, 2019 in connection with a reverse merger. In October 2018, Clinigence was incorporated as
a wholly-owned subsidiary of Clinigence LLC. The Company is a population health analytics company that provides turnkey SaaS solutions
that enable connected intelligence across the care continuum by transforming massive amounts of data into actionable insights. The Companys
solutions help healthcare organizations throughout the United States improve the quality and cost-effectiveness of care, enhance population
health management and optimize provider networks. The Company enables risk-bearing healthcare organizations achieve their objectives
on the path to value-based care. The Companys platform automatically extracts and delivers targeted data insights from its cloud-based
analytics engine directly to the workflows and technologies of its customers. This enhances end-user workflows with actionable analytics,
seamlessly delivers data from disparate sources to the point of engagement, automates the delivery of data to ensure on-time access,
and reduces dependency on non-essential applications from the end-users workflow. All of this allows the healthcare organization
to enable population health management, manage cost and utilization, improve quality, identify gaps in care, risk stratify and target
patients, increase collaboration among providers and to optimize network provider performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHA
was organized to acquire a series of companies providing a broad array of health and managed care services to Medicare members. AHAs
initial focus is on acquiring Accountable Care Organizations (ACOs), Managed Service Organizations (MSOs)
and Primary Care Physician Practices (PCPs) with significant numbers of Medicare members.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHP
is a privately held medical management company and provider network that manages its affiliated medical group, AHP Independent Physicians
Association.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Interim
Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following condensed consolidated balance sheet as of December 31, 2020, which has been derived from audited financial statements, and
the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions
to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP
for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2021 are not necessarily
indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should
be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included
in the Companys Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on April 5,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Business
Acquisitions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Merger
With AHP Management Inc.&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (Parent or the Company), AHP, Inc.,
a California corporation (AHP), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (Merger
Sub), and Robert Chan (the Shareholders Representative) entered into an agreement and plan of merger (the
AHP Merger Agreement). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021
(the AHP Closing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, h&lt;span style="background-color: white"&gt;ereafter referred
to as the AHP Acquisition.&lt;/span&gt; As a result of the Acquisition, Merger Sub ceased to exist, and AHP became the surviving
corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHP (the AHP Stockholders)
have a direct equity ownership in Clinigence. Merger Sub was renamed AHP Management Inc. Merger Sub was originally incorporated in Delaware
on January 26, 2021 and had no operating activity prior to the reported transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHP
was a privately held company with controlling interest in its affiliate Associated Hispanic Physicians of Southern California
IPA, a California Medical corporation, (AHPIPA). A key term of the AHP Merger Agreement is that at Closing, AHP Management
Inc entered into a Management Services Agreement with AHPIPA (the Management Services Agreements) making AHPIPA a Variable
Interest Entity (VIE) of Clinigence.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Merger
With Accountable Healthcare America, Inc.&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (Parent or the Company), Accountable
Healthcare America, Inc., a Delaware corporation (AHA), and AHA Acquisition Corp., a Delaware corporation, a wholly owned
subsidiary of Parent (Merger Sub) entered into an agreement and plan of merger (the AHA Merger Agreement).
The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the AHA Closing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, h&lt;span style="background-color: white"&gt;ereafter referred
to as the AHA Acquisition.&lt;/span&gt; As a result of the Acquisition, Merger Sub ceased to exist, and AHA became the surviving
corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHA (the AHA Stockholders)
have a direct equity ownership in Clinigence. Merger Sub was renamed Accountable Healthcare America, Inc. Merger Sub was originally incorporated
in Delaware on January 2, 2020 and had no operating activity prior to the reported transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--PreferredStockDescription_c20210101__20210930" title="Preferred Stock description"&gt;Pursuant
to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at
$2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company
Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder
was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing,
the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants
assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options
and warrants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents the preliminary allocation of the value of the common shares issued for AHA to the acquired identifiable assets,
liabilities assumed and goodwill:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hdei--LegalEntityAxis__custom--AHAMember_zE2svEngTCQ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zgUpeOiOWTy" style="display: none"&gt;Schedule of Recognized Identified Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49A_20210930__dei--LegalEntityAxis__custom--AHAMember_z9OXWPJvAGea" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;697,191&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInAcmg_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Investment in ACMG&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,134,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPhpTechnology_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PHP technology&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,729,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanToClinigence_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loan to Clinigence&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;85,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zlkTV1zDLbAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,143,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty_iNI_pp0p0_di_zb6KeNCMkhY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due to related party&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(128,176&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable_iNI_pp0p0_di_z8uYYSOkssoi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,631,942&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertibleNotesPayable_iI_pp0p0_d0_zaoA2P58xa2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;21,115,272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,859,339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zb4jrflYSp56" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents the preliminary allocation of the value of the common shares issued for AHP to the acquired identifiable assets,
liabilities assumed and goodwill:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zrBA3qqRfRSg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zYeBz0I6LyOi" style="display: none"&gt;Schedule of Recognized Identified Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49E_20210930__dei--LegalEntityAxis__custom--AHPMember_zlOODUgasiTh" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0_zHheAHMfcn91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,105,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;269,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;26,178&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMemberRelationships_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,444,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;545,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zMzRUX6pBm5e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,683,896&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0_zrKbijiYQHe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;31,433,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice_iI_pp0p0_zvuRcDSiNrAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,140,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zbHzOF4HNgth" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the AHP Merger Agreement, &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20210930__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_zYRHkfqfagY" title="Stock issued"&gt;1,076,372&lt;/span&gt; of
the &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20210930_zKQ2v7wUZrM6"&gt;19,000,000&lt;/span&gt; of Company Shares issued to AHP valued at $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20210930__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_zrfHfmkWCoAh" title="Stock price per share"&gt;2.06 &lt;/span&gt;per share were Litigation Holdback shares, related to two shareholders
who were engaged in an Arbitration case with AHP at the time of Closing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;AHP lost the Arbitration case and on September 13,
2021, the Arbitration Court granted the Claimants an award in the amount of $&lt;span id="xdx_905_eus-gaap--StockIssued1_c20210901__20210913__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_zfxINhDqVLEf" title="Stock issued amount"&gt;1,091,896&lt;/span&gt; and the Litigation Holdback shares were retained
by the Company. Therefore, the Company paid the cash settlement for $&lt;span id="xdx_907_ecustom--CashSettlementAmount_c20210901__20210913__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_zOJ1Hs1rCNOh" title="Cash settlement amount"&gt;1,091,896&lt;/span&gt;, reduced goodwill by $&lt;span id="xdx_901_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_c20210913__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_z0yQxvWqXyqh" title="Goodwill"&gt;1,122,636&lt;/span&gt; and reduced equity for
$&lt;span id="xdx_902_eus-gaap--EquityFairValueDisclosure_iI_c20210930__us-gaap--BusinessAcquisitionAxis__custom--AHPMergerAgreementMember_zYHSAnbtBW16" title="Equity"&gt;2,216,250&lt;/span&gt; representing the original value of the shares returned. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20210930_z0OWlGdaRjY7" title="Accumulated deficit"&gt;27,305,852&lt;/span&gt; at
September 30, 2021. This factor, among others, raise substantial doubt about the ability of the Company to continue as a going concern
for the next twelve months from the date that the financial statements are issued.Managements plans and assessment
of the probability that such plans will mitigate and alleviate any substantial doubt about the Companys ability to continue as
a going concern, is dependent upon the ability to attain funding to secure additional resources to generate sufficient revenues and increased
margin, which without these represent the principal conditions that raise substantial doubt about our ability to continue as a going
concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
a result of the spread of the COVID-19 coronavirus, economic uncertainties have arisen which are likely to negatively impact operations.
Other financial impact could occur though such potential impact is unknown at this time. A pandemic typically results in social distancing,
travel bans and quarantine, and this may limit access to our facilities, customers, management, support staff and professional advisors.
These factors, in turn, may not only impact our operations, financial condition and demand for our goods and services but our overall
ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with
the Securities and Exchange Commission.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further
issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working
capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next
twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through
the proceeds of a private placement of equity and debt instruments. In connection with the Companys business plan, management
anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with
a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities,
and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term
operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders.
Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available
upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be
able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern.&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the nine months ended September 30, 2021, our operations lost $&lt;span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iN_pp0p0_di_c20210101__20210930_zhIk8tauYGz" title="Income (loss) from continuing operations"&gt;9,074,547&lt;/span&gt;, of which approximately $&lt;span id="xdx_902_ecustom--NonCashOperation_c20210101__20210930_zFLdOaBBTUa" title="Non Cash"&gt;3,812,750&lt;/span&gt; was non-cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2021, we had total current assets of $&lt;span id="xdx_90E_eus-gaap--AssetsCurrent_c20210930_pp0p0" title="Total current assets"&gt;11,607,729&lt;/span&gt; and current liabilities of $&lt;span id="xdx_904_eus-gaap--LiabilitiesCurrent_c20210930_pp0p0" title="Total current liabilities"&gt;6,534,518&lt;/span&gt; resulting in working capital of
$&lt;span id="xdx_90E_ecustom--WorkingCapitalDeficit_c20210930_pp0p0" title="Working capital deficit"&gt;5,073,211&lt;/span&gt;, of which $&lt;span id="xdx_903_eus-gaap--DueToRelatedPartiesCurrent_c20210930_pp0p0" title="Due to related parties"&gt;128,176&lt;/span&gt; was related party notes payable. At September 30, 2021, we had total assets of $&lt;span id="xdx_904_eus-gaap--Assets_iI_pp0p0_c20210930_zflQi33cvfhf" title="Assets"&gt;83,271,518&lt;/span&gt; and total liabilities
of $&lt;span id="xdx_90F_eus-gaap--Liabilities_c20210930_pp0p0" title="Total liabilities"&gt;9,331,900&lt;/span&gt;, resulting in stockholders equity of $&lt;span id="xdx_90C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_pp0p0_c20210930_zNL1NAdYmqJ" title="Total stockholders' equity (deficiency)"&gt;73,939,618&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:SaleOfStockPricePerShare id="f811" decimals="INF" contextRef="c210" unitRef="usd1">2.06</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="f812" decimals="0" contextRef="c211" unitRef="usd">2171875.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:IncreaseDecreaseInCustomerDeposits id="f813" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:IncreaseDecreaseInCustomerDeposits>
  <clinigence.com:PreferredStockDescription id="f814" contextRef="c5">Pursuant
to the AHP Merger Agreement, at the Closing, the former AHP Stockholders were entitled to receive 19,000,000 Company Shares valued at
$2.06 per share, inclusive of outstanding AHP options and warrants assumed by the Company, which constitutes 45% of the outstanding Company
Shares on a fully diluted basis inclusive of outstanding options and warrants. For each share of AHP Shares, each former AHP Stockholder
was entitled to receive 19,000,000 shares of Company Shares valued at $2.06 per share. Pursuant to the AHA Merger Agreement, at the Closing,
the former AHA Stockholders were entitled to receive 14,034,472 Company Shares, inclusive of certain outstanding AHA options and warrants
assumed by the Company, which constitutes 35% of the outstanding Company Shares on a fully diluted basis inclusive of outstanding options
and warrants.</clinigence.com:PreferredStockDescription>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="f815" decimals="INF" contextRef="c212" unitRef="shares">750000.0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:SharePrice id="f816" decimals="INF" contextRef="c213" unitRef="usd1">1.75</us-gaap:SharePrice>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f817" decimals="INF" contextRef="c214" unitRef="shares">1241072.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="f818" decimals="0" contextRef="c12" unitRef="usd">-21730.0</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock id="f819" contextRef="c196">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hdei--LegalEntityAxis__custom--AHAMember_zE2svEngTCQ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zgUpeOiOWTy" style="display: none"&gt;Schedule of Recognized Identified Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49A_20210930__dei--LegalEntityAxis__custom--AHAMember_z9OXWPJvAGea" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;697,191&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInAcmg_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Investment in ACMG&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,134,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPhpTechnology_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;PHP technology&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,729,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanToClinigence_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loan to Clinigence&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;85,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zlkTV1zDLbAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,143,106&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty_iNI_pp0p0_di_zb6KeNCMkhY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due to related party&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(128,176&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable_iNI_pp0p0_di_z8uYYSOkssoi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,631,942&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertibleNotesPayable_iI_pp0p0_d0_zaoA2P58xa2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;21,115,272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;28,859,339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:SaleOfStockPricePerShare id="f820" decimals="INF" contextRef="c215" unitRef="usd1">2.06</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="f821" decimals="0" contextRef="c5" unitRef="usd">-31665.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <clinigence.com:CommonStockShare id="f822" decimals="INF" contextRef="c5" unitRef="shares">933242.0</clinigence.com:CommonStockShare>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f823" decimals="0" contextRef="c12" unitRef="usd">-37401.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="f824" decimals="INF" contextRef="c216" unitRef="shares">19000000.0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="f825" decimals="INF" contextRef="c212" unitRef="shares">14198615.0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f826" decimals="INF" contextRef="c217" unitRef="shares">228721.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther id="f827" decimals="0" contextRef="c208" unitRef="usd">2100.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="f828" decimals="0" contextRef="c12" unitRef="usd">-148498.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInAcmg id="f829" decimals="0" contextRef="c208" unitRef="usd">7134000.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentInAcmg>
  <us-gaap:SharesIssuedPricePerShare id="f830" decimals="INF" contextRef="c210" unitRef="usd1">2.06</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="f831" decimals="INF" contextRef="c218" unitRef="usd1">0.65</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f832" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice id="f833" decimals="0" contextRef="c219" unitRef="usd">39140000.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice>
  <us-gaap:CashFDICInsuredAmount id="f834" decimals="0" contextRef="c6" unitRef="usd">250000.0</us-gaap:CashFDICInsuredAmount>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPhpTechnology id="f835" decimals="0" contextRef="c208" unitRef="usd">2729000.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPhpTechnology>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f836" decimals="0" contextRef="c12" unitRef="usd">-1557995.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanToClinigence id="f837" decimals="0" contextRef="c208" unitRef="usd">85000.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanToClinigence>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f838" decimals="INF" contextRef="c220" unitRef="shares">153606.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable id="f839" decimals="0" contextRef="c208" unitRef="usd">1143106.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <us-gaap:IncomeTaxDisclosureTextBlock id="f840" contextRef="c5">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_z8ci8Fe9v59e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
13 - &lt;span id="xdx_82A_zSmKMuqR3Zk3"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
full valuation allowance was recorded against the Companys net deferred tax assets. A valuation allowance must be established
if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available
positive and negative evidence, which includes, among other things, the Companys most recent results of operations and expected
future profitability. Based on the Companys cumulative losses in recent years, a full valuation allowance against the Companys
deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.
A deferred tax liability of $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_c20210930_pp0p0" title="Deferred tax liability"&gt;2,429,500&lt;/span&gt; was recorded as of September 30, 2021 for the intangible assets acquired from AHA and AHP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty id="f841" decimals="0" contextRef="c208" unitRef="usd">128176.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueToRelatedParty>
  <us-gaap:DecreaseInRestrictedCash id="f842" decimals="0" contextRef="c12" unitRef="usd">49693.0</us-gaap:DecreaseInRestrictedCash>
  <clinigence.com:PaymentToAhpShareholderForLitigationSettlement id="f843" decimals="0" contextRef="c5" unitRef="usd">1094689.0</clinigence.com:PaymentToAhpShareholderForLitigationSettlement>
  <us-gaap:ConcentrationRiskPercentage1 id="f844" decimals="INF" contextRef="c221" unitRef="pure">0.14</us-gaap:ConcentrationRiskPercentage1>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable id="f845" decimals="0" contextRef="c208" unitRef="usd">1631942.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="f846" decimals="0" contextRef="c6" unitRef="usd">2429500.0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f847" decimals="0" contextRef="c12" unitRef="usd">500.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertibleNotesPayable id="f848" decimals="0" contextRef="c208" unitRef="usd">0.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedConvertibleNotesPayable>
  <us-gaap:CashAcquiredFromAcquisition id="f849" decimals="0" contextRef="c5" unitRef="usd">3803267.0</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:ConcentrationRiskCreditRisk id="f850" contextRef="c5">&lt;p id="xdx_805_eus-gaap--ConcentrationRiskCreditRisk_zenXpuxVtdvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
14  &lt;span id="xdx_82E_zoICVZYjIyok"&gt;Concentrations and Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Sales
and Accounts Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company had sales to two customers which accounted for approximately &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersMember_zo4zhgBb9wy7" title="Concentration percentage"&gt;22&lt;/span&gt;% and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zRCv17DsCJU5" title="Concentration percentage"&gt;18&lt;/span&gt;%, respectively of total sales for the nine months ended
September 30, 2021. The two customers had no accounts receivable balances at September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company had sales to three customers which accounted for approximately &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zfivMLhEhdUb" title="Concentration percentage"&gt;14&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zwLlRDVng084" title="Concentration percentage"&gt;10&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersThreeMember_zR5pZFRILlga" title="Concentration percentage"&gt;10&lt;/span&gt;%, respectively of total sales for the nine months
ended September 30, 2020. Two of the three customers accounted for &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__srt--MajorCustomersAxis__custom--CustomersMember_zK8Y7MgkjcC9" title="Concentration percentage"&gt;24&lt;/span&gt;% and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomersMember_zpa30HHiQwCk" title="Concentration percentage"&gt;14&lt;/span&gt;%, respectively of accounts receivable at September 30,
2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_c20210930_pp0p0" title="FDIC"&gt;250,000&lt;/span&gt;.
Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did
not have any interest-bearing accounts at September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="f851" decimals="0" contextRef="c5" unitRef="usd">7381563.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet id="f852" decimals="0" contextRef="c208" unitRef="usd">21115272.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice id="f853" decimals="0" contextRef="c208" unitRef="usd">28859339.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice>
  <us-gaap:ProceedsFromNotesPayable id="f854" decimals="0" contextRef="c5" unitRef="usd">413917.0</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables id="f855" decimals="0" contextRef="c219" unitRef="usd">269315.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <us-gaap:ProceedsFromLoans id="f856" decimals="0" contextRef="c5" unitRef="usd">85000.0</us-gaap:ProceedsFromLoans>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents id="f857" decimals="0" contextRef="c219" unitRef="usd">3105877.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:ConcentrationRiskPercentage1 id="f858" decimals="INF" contextRef="c222" unitRef="pure">0.22</us-gaap:ConcentrationRiskPercentage1>
  <clinigence.com:PaymentToAhpShareholderForLitigationSettlement id="f859" decimals="0" contextRef="c12" unitRef="usd">-0.0</clinigence.com:PaymentToAhpShareholderForLitigationSettlement>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock id="f860" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zrBA3qqRfRSg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zYeBz0I6LyOi" style="display: none"&gt;Schedule of Recognized Identified Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49E_20210930__dei--LegalEntityAxis__custom--AHPMember_zlOODUgasiTh" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0_zHheAHMfcn91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,105,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;269,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deposits and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;26,178&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMemberRelationships_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,444,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;545,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zMzRUX6pBm5e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2,683,896&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0_zrKbijiYQHe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;31,433,526&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchasePrice_iI_pp0p0_zvuRcDSiNrAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,140,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:SharesIssued id="f861" decimals="INF" contextRef="c223" unitRef="shares">1076372.0</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromLoans id="f862" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:ProceedsFromLoans>
  <us-gaap:ConcentrationRiskPercentage1 id="f863" decimals="INF" contextRef="c224" unitRef="pure">0.18</us-gaap:ConcentrationRiskPercentage1>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOtherAssets id="f864" decimals="0" contextRef="c219" unitRef="usd">26178.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDepositsAndOtherAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet id="f865" decimals="0" contextRef="c219" unitRef="usd">31433526.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:CashAcquiredFromAcquisition id="f866" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:CashAcquiredFromAcquisition>
  <clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMemberRelationships id="f867" decimals="0" contextRef="c219" unitRef="usd">6444000.0</clinigence.com:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMemberRelationships>
  <us-gaap:ConcentrationRiskPercentage1 id="f868" decimals="INF" contextRef="c225" unitRef="pure">0.1</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f869" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets id="f870" decimals="0" contextRef="c219" unitRef="usd">545000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable id="f871" decimals="0" contextRef="c219" unitRef="usd">2683896.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <us-gaap:ConcentrationRiskPercentage1 id="f872" decimals="INF" contextRef="c226" unitRef="pure">0.1</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f873" decimals="0" contextRef="c12" unitRef="usd">50193.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:SaleOfStockPricePerShare id="f874" decimals="INF" contextRef="c223" unitRef="usd1">2.06</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ConcentrationRiskPercentage1 id="f875" decimals="INF" contextRef="c227" unitRef="pure">0.24</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RepaymentsOfNotesPayable id="f876" decimals="0" contextRef="c5" unitRef="usd">16765.0</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:StockIssued1 id="f877" decimals="0" contextRef="c228" unitRef="usd">1091896.0</us-gaap:StockIssued1>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="f878" decimals="0" contextRef="c5" unitRef="usd">2793578.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ConcentrationRiskPercentage1 id="f879" decimals="INF" contextRef="c229" unitRef="pure">0.14</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f880" decimals="INF" contextRef="c6" unitRef="shares">19000000.0</us-gaap:SharesIssued>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="f881" decimals="0" contextRef="c12" unitRef="usd">-2656.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
  <clinigence.com:NonCashOperation id="f882" decimals="0" contextRef="c5" unitRef="usd">3812750.0</clinigence.com:NonCashOperation>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaises id="f883" decimals="0" contextRef="c5" unitRef="usd">678000.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaises>
  <us-gaap:ProceedsFromRelatedPartyDebt id="f884" decimals="0" contextRef="c230" unitRef="usd">30000.0</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="f885" decimals="0" contextRef="c12" unitRef="usd">47537.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromWarrantExercises id="f886" decimals="0" contextRef="c5" unitRef="usd">60937.0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="f887" decimals="0" contextRef="c231" unitRef="usd">128176.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <clinigence.com:CashSettlementAmount id="f888" decimals="0" contextRef="c228" unitRef="usd">1091896.0</clinigence.com:CashSettlementAmount>
  <us-gaap:EquityFairValueDisclosure id="f889" decimals="0" contextRef="c223" unitRef="usd">2216250.0</us-gaap:EquityFairValueDisclosure>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="f890" decimals="0" contextRef="c12" unitRef="usd">120000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="f891" contextRef="c5">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpb3qK1r6sU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
15 - &lt;span id="xdx_820_zHvZsNtfLSG6"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Due
to Related Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due
to related parties with a balance of $&lt;span id="xdx_90B_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20210930_pp0p0" title="Due to related parties"&gt;128,176&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20201231_pp0p0" title="Due to related parties"&gt;30,000&lt;/span&gt; at September 30, 2021 and December 31, 2020, respectively, does not bear interest
and is payable on demand. The Companys former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband
of the Companys Chief Financial Officer, who was held personally responsible by the credit card company for the unpaid balance.
The balance of $&lt;span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndFormerOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--AssumedLiabilitiesMember_pp0p0" title="Due to related parties"&gt;128,176&lt;/span&gt; was included in the assumed liabilities of the AHA merger transaction. A shareholder and former officer made
a $&lt;span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndFormerOfficerMember_pp0p0" title="Proceeds from related party debt"&gt;30,000&lt;/span&gt; non-interest bearing loan to the Company on December 31, 2020, which was repaid with common stock on &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderAndFormerOfficerMember_zMPY8Oi5HUgd" title="Maturity date"&gt;January 28, 2021&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="f892" decimals="0" contextRef="c6" unitRef="usd">128176.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:ProceedsFromWarrantExercises id="f893" decimals="0" contextRef="c12" unitRef="usd">0.0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets id="f894" decimals="0" contextRef="c232" unitRef="usd">1122636.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="f895" contextRef="c5">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zGzHl3CNdjH" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
16  &lt;span id="xdx_82D_z9v19jeusmxj"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Employment
Arrangements With Executive Officers&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company entered into 3-year employment agreements with Elisa Luqman and Dr. Lawrence Schimmel. Pursuant to the employment agreements
with Ms. Luqman and Dr. Schimmel, each is entitled to receive a base annual salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElisaLuqmanMember_pp0p0" title="Base Salary"&gt;150,000&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LawrenceSchimmelMember_pp0p0" title="Base Salary"&gt;180,000&lt;/span&gt;, respectively, during the
term, which continue to be obligations of the Company at Closing. Dr. Hosseinion entered into a 5-year employment agreement with the
Company which became effective at Closing and pursuant to which Dr. Hosseinion is entitled to receive a base salary of $&lt;span id="xdx_900_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHosseinionMember_pp0p0" title="Base Salary"&gt;250,000&lt;/span&gt; during
the term. AHP had entered into a 2-year employment agreement with Michael Bowen and a 5-year employment agreements with Fred Sternberg
and Andrew Barnett. Pursuant to the employment agreements with Mr. Sternberg, Mr. Bowen, and Mr. Barnett, each is entitled to receive
a base annual salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSternbergMember_pp0p0" title="Base Salary"&gt;250,000&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBowenMember_pp0p0" title="Base Salary"&gt;150,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--SalariesAndWages_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBarnettMember_pp0p0" title="Base Salary"&gt;250,000&lt;/span&gt;, respectively, during the term, which became obligations of the Company at Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the employment agreements with the named officers, upon termination, each such individual would be entitled to receive payment of
all salary and benefits accrued up to the termination date of his or her employment in all employment termination events. Thereafter,
Ms. Luqman would be entitled to receive twelve (12) months of base salary as a severance payment, Dr. Schimmel would be entitled to receive
twenty-four (24) months of base salary as a severance payment, Dr. Hosseinion would be entitled to receive twenty four (24) months of
base salary as a severance payment, Mr. Sternberg would be entitled to receive twenty four (24) months of base salary as a severance
payment Mr. Bowen would be entitled to receive twelve (12) months of base salary as a severance payment, and Mr. Barnett would each be
entitled to the balance of the remaining months under his employment agreement of base salary as a severance payment, upon termination
of his or her employment by the Company without cause or by such individual for good reason.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson,
MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $&lt;span id="xdx_90D_eus-gaap--SalariesAndWages_c20210101__20210930_pp0p0" title="Base Salary"&gt;75,000&lt;/span&gt; per year, bonuses based upon objectives
set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements
restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements
or two years following the termination of their respective employment. The employment agreements were terminated in connection with the
sale of HealthDatix effective March 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;







</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="f896" decimals="0" contextRef="c37" unitRef="usd">30000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:ProceedsFromNotesPayable id="f897" decimals="0" contextRef="c12" unitRef="usd">461125.0</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:SalariesAndWages id="f898" decimals="0" contextRef="c233" unitRef="usd">250000.0</us-gaap:SalariesAndWages>
  <us-gaap:Cash id="f899" decimals="0" contextRef="c55" unitRef="usd">27742.0</us-gaap:Cash>
  <clinigence.com:WorkingCapitalDeficit id="f900" decimals="0" contextRef="c6" unitRef="usd">5073211.0</clinigence.com:WorkingCapitalDeficit>
  <us-gaap:DebtInstrumentMaturityDate id="f901" contextRef="c230">2021-01-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:RepaymentsOfNotesPayable id="f902" decimals="0" contextRef="c12" unitRef="usd">108359.0</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:SalariesAndWages id="f903" decimals="0" contextRef="c234" unitRef="usd">150000.0</us-gaap:SalariesAndWages>
  <us-gaap:InterestPaidNet id="f904" decimals="0" contextRef="c5" unitRef="usd">447691.0</us-gaap:InterestPaidNet>
  <us-gaap:SalariesAndWages id="f905" decimals="0" contextRef="c235" unitRef="usd">150000.0</us-gaap:SalariesAndWages>
  <srt:ScheduleOfCondensedIncomeStatementTableTextBlock id="f906" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zUbLd9OXRtr9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zNUFX54JnIAe" style="display: none"&gt;Schedule of consolidated statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_499_20210101_20210930_us-gaap--StatementOperatingActivitiesSegmentAxis_us-gaap--SegmentDiscontinuedOperationsMember" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,958&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CostOfRevenue_iN_pp0p0_di_zXsCSABHRuj9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(6,795&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_iN_pp0p0_di_zOOQremEisjj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(101,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_iN_pp0p0_di_zkhOR1cCipW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_iN_pp0p0_di_zt7UpzugJqw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Interest
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_z2NHNZqgNvY9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(102,275&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Gain
    on disposal of HealthDatix&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;142,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Income
    from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,752&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
  <us-gaap:SalariesAndWages id="f907" decimals="0" contextRef="c236" unitRef="usd">250000.0</us-gaap:SalariesAndWages>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f908" decimals="0" contextRef="c5" unitRef="usd">7161652.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <clinigence.com:DiscontinuedOperationsTextBlock id="f909" contextRef="c5">&lt;p id="xdx_802_ecustom--DiscontinuedOperationsTextBlock_z9to1vIB8lo9" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
2  &lt;span id="xdx_82C_zFY9ymQNGQV6"&gt;Discontinued Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Sale
of Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 21, 2020(effective March 1, 2020) the Company completed the sale of HealthDatix, Inc., a Florida corporation (HDX
FL) to Jerry Robinson, Mary-Jo Robinson and Kathleen Shepherd (HDX Management) in accordance with a Stock
Purchase Agreement (the Purchase Agreement) by and between the Company and HDX Management. Pursuant to the Purchase
Agreement, the total consideration paid for the outstanding capital stock of HDX FL was the execution of Settlement and Release Agreements
by HDX Management, releasing the Company from all obligations pursuant to certain HDX Management Employment Agreements dated April 1,
2017, and remittance of 1,000 shares of HDX common stock previously issued to HDX Management. As per the Purchase Agreement, the Companys
operations of HDX FL ended February 29, 2020 and HDX Managements operation of the business is effective as of March 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
components of loss from discontinued operations presented in the consolidated statements of operations for the nine months ended September
30, 2021 are presented as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zUbLd9OXRtr9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zNUFX54JnIAe" style="display: none"&gt;Schedule of consolidated statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_499_20210101_20210930_us-gaap--StatementOperatingActivitiesSegmentAxis_us-gaap--SegmentDiscontinuedOperationsMember" style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--Revenues_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,958&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CostOfRevenue_iN_pp0p0_di_zXsCSABHRuj9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(6,795&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_iN_pp0p0_di_zOOQremEisjj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(101,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_iN_pp0p0_di_zkhOR1cCipW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_iN_pp0p0_di_zt7UpzugJqw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Interest
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_z2NHNZqgNvY9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(102,275&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Gain
    on disposal of HealthDatix&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;142,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Income
    from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,752&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</clinigence.com:DiscontinuedOperationsTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense id="f910" decimals="0" contextRef="c237" unitRef="usd">101100.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:SalariesAndWages id="f911" decimals="0" contextRef="c238" unitRef="usd">180000.0</us-gaap:SalariesAndWages>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaises id="f912" decimals="0" contextRef="c12" unitRef="usd">-0.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaises>
  <us-gaap:Revenues id="f913" decimals="0" contextRef="c237" unitRef="usd">5958.0</us-gaap:Revenues>
  <us-gaap:SalariesAndWages id="f914" decimals="0" contextRef="c239" unitRef="usd">250000.0</us-gaap:SalariesAndWages>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f915" decimals="0" contextRef="c5" unitRef="usd">5984511.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:SalariesAndWages id="f916" decimals="0" contextRef="c5" unitRef="usd">75000.0</us-gaap:SalariesAndWages>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f917" decimals="0" contextRef="c12" unitRef="usd">472766.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CostOfRevenue id="f918" decimals="0" contextRef="c237" unitRef="usd">6795.0</us-gaap:CostOfRevenue>
  <us-gaap:Cash id="f919" decimals="0" contextRef="c37" unitRef="usd">26931.0</us-gaap:Cash>
  <us-gaap:VariableInterestEntityDisclosureTextBlock id="f920" contextRef="c5">&lt;p id="xdx_801_eus-gaap--VariableInterestEntityDisclosureTextBlock_zo9YovzNwrT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
17 - &lt;span id="xdx_82D_zcocnOkdyETj"&gt;Variable Interest Entities (VIEs)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity
investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right
to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has
both the power to direct the activities of the VIE that most significantly affect the entitys economic performance and the obligation
to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether
it is the primary beneficiary of a VIE. See Note 2 to the accompanying consolidated financial statements for information on how the Company
determines VIEs and its treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table includes assets that can only be used to settle the liabilities of AHPIPA and the creditors of AHPIPA have no recourse
to the Company. These assets and liabilities are included in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConsolidatedBalanceSheets_ziL0DFyhq4ef" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Variable Interest Entities (VIEs) (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zmfikRgRNHW8" style="display: none"&gt;Schedule of consolidated balance sheets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20210930_dei--LegalEntityAxis_custom--AHPIPAMember" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,795,216&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,840&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,162,995&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Goodwill_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;31,733,526&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;108,842&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,685,414&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAssets_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;38,527,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,690,777&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i02B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable
    and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,425,112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
    liability - current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,440&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,470,552&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesNoncurrentAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long-term Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
    liability  long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;67,882&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Liabilities_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,538,434&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;







</us-gaap:VariableInterestEntityDisclosureTextBlock>
  <us-gaap:InterestExpense id="f921" decimals="0" contextRef="c237" unitRef="usd">263.0</us-gaap:InterestExpense>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="f922" decimals="0" contextRef="c12" unitRef="usd">-1037692.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="f923" decimals="0" contextRef="c240" unitRef="usd">71840.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:DepreciationAndAmortization id="f924" decimals="0" contextRef="c237" unitRef="usd">75.0</us-gaap:DepreciationAndAmortization>
  <us-gaap:Cash id="f925" decimals="0" contextRef="c6" unitRef="usd">6011442.0</us-gaap:Cash>
  <us-gaap:Cash id="f926" decimals="0" contextRef="c43" unitRef="usd">1065434.0</us-gaap:Cash>
  <us-gaap:OperatingIncomeLoss id="f927" decimals="0" contextRef="c237" unitRef="usd">102275.0</us-gaap:OperatingIncomeLoss>
  <clinigence.com:ScheduleOfConsolidatedBalanceSheets id="f928" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--ScheduleOfConsolidatedBalanceSheets_ziL0DFyhq4ef" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Variable Interest Entities (VIEs) (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zmfikRgRNHW8" style="display: none"&gt;Schedule of consolidated balance sheets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20210930_dei--LegalEntityAxis_custom--AHPIPAMember" style="text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,795,216&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;295,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;71,840&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,162,995&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Goodwill_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;31,733,526&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset,
    net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;108,842&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,685,414&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAssets_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;38,527,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;41,690,777&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i02B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable
    and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,425,112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
    liability - current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;45,440&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,470,552&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesNoncurrentAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long-term Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
    liability  long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;67,882&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Liabilities_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,538,434&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:ScheduleOfConsolidatedBalanceSheets>
  <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax id="f929" decimals="0" contextRef="c237" unitRef="usd">142027.0</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
  <us-gaap:AssetsCurrent id="f930" decimals="0" contextRef="c240" unitRef="usd">3162995.0</us-gaap:AssetsCurrent>
  <clinigence.com:InvestmentInAhaInExchangeOfAssetsSoldAndLiabilitiesAssumed id="f931" decimals="0" contextRef="c5" unitRef="usd">0.0</clinigence.com:InvestmentInAhaInExchangeOfAssetsSoldAndLiabilitiesAssumed>
  <us-gaap:ReceivablesPolicyTextBlock id="f932" contextRef="c5">&lt;p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_z7IJzRHRPQmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zYUSfNpEYZ8a"&gt;Accounts
Receivable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance
for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables,
including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.
The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial
obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability
to render payment. As of September 30, 2021, no customers represented more than 10% of total accounts receivable&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:AccountsReceivableNetCurrent id="f933" decimals="0" contextRef="c240" unitRef="usd">295939.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InterestPaidNet id="f934" decimals="0" contextRef="c12" unitRef="usd">16130.0</us-gaap:InterestPaidNet>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="f935" contextRef="c5">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zFIwNsTDGn81" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
3 &lt;span id="xdx_820_zGRlUqK9Lt0c"&gt; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zoyuoyo8SKme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zh62p15u3QMg"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable
Healthcare America Inc., and AHP Management Inc.All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zHfbIJt67ASk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zeAhGN2S1ywl"&gt;Use
of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The
Companys significant estimates used in these financial statements include, but are not limited to, accounts receivable reserves,
the valuation allowance related to the Companys deferred tax assets, the recoverability and useful lives of long-lived assets,
debt conversion features, stock-based compensation, certain assumptions related to the valuation of the reserved shares and the assets
acquired and liabilities assumed related to the Companys acquisitions. Certain of the Companys estimates could be affected
by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external
factors could have an effect on the Companys estimates and could cause actual results to differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;







&lt;p id="xdx_843_ecustom--VariableInterestEntityPolicyTextBlock_z8Hb6s99Aqba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zgHV0MY8Ozwk"&gt;Variable
Interest Entities&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned
by the Company in accordance with the consolidation guidance. The evaluation considers all of the Companys variable interests,
including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity
must meet both of the following criteria:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            entity has a legal structure that has been established to conduct business activities and
                                            to hold assets; such entity can be in the form of a partnership, limited liability company,
                                            or corporation, among others; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            Company has a variable interest in the legal entity  i.e., variable interests that
                                            are contractual, such as equity ownership, or other financial interests that change with
                                            changes in the fair value of the entitys net assets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting.
If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model
if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities
that are not VIEs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.
The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.
The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s)
of voting rights); or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.
The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they
lack any of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.
The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entitys
economic performance, as evidenced by:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i.
Substantive participating rights in day-to-day management of the entitys activities; or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ii.
Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iii.
The obligation to absorb the entitys expected losses; or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iv.
The right to receive the entitys expected residual returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and
evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Variable
interest model&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis
is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company
 that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIEs economic
performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially
be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.
Refer to Note 17  Variable Interest Entities (VIEs) to the consolidated financial statements for information on
the Companys consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company
may account for the investment using the equity method of accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zozxAnR2Bnbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zYNLbtspXHpe"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase.
The Company does not have any cash equivalents as of September 30, 2021 and December 31, 2020. The Company is exposed to credit risk
in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested
are in excess of amounts that are insured.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_z7IJzRHRPQmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zYUSfNpEYZ8a"&gt;Accounts
Receivable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance
for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables,
including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.
The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial
obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability
to render payment. As of September 30, 2021, no customers represented more than 10% of total accounts receivable&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgHhl0EBCXmc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zs9zjVDf8ari"&gt;Property
and equipment and depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfEstimatedLivesOfRespectiveAssetsTableTextBlock_zBVPEhL1WJ04" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span id="xdx_8BE_zPGB96AYLX0h" style="display: none"&gt;Schedule of estimated lives of respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; width: 45%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    equipment and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zL4sqXuPn3T8" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zkSoJgJV5Exd" title="Office equipment useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    hardware&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareMember_z2esPoiBlkoa" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zETQaQPR7S5j" title="Office equipment useful life"&gt;3&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Development
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopmentEquipmentMember_zQ6fZwTK5E3a" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_84F_ecustom--AmortizationPolicyTextBlock_zfErM7Ncqmee" style="font: 10pt Times New Roman, Times, Serif; margin: 13.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zvNIWl97Ulcd"&gt;Amortization&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets are amortized using the straight line method over the estimated lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfEstimatedLivesOfIntangibleAssetsTableTextBlock_zafzW1UYLwI6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zQwIEYOvw22l" style="display: none"&gt;Schedule of estimated lives of the respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Population Health
    Platform technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_znDdkGe3rJNf" title="Intangible assets useful life"&gt;11&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zK0xXNDNGZSh" title="Intangible assets useful life"&gt;15&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zuBPXGw5vfo6" title="Intangible assets useful life"&gt;6&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zJiP6GdcAwCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zm24XLFXgBHl"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill
represents the net identifiable assets acquired and the liabilities assumed of AHA and AHP and the fair market value of the common shares
issued by the Company for the acquisition of AHA and AHP. In accordance with ASC Topic No. 350 Intangibles  Goodwill and
Other), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value
based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss
is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be
sufficient to recover the assets carrying amount, an impairment loss is charged to expense in the period identified. No impairment
was recorded during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zecMDEU15Uu2" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zzeRDV3mk5A"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances
dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets,
the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or
factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the
Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level
for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is
less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and
its estimated fair value, generally measured by the present value of the estimated cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionDeferredRevenue_zSoLwGpSt7ci" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z6n8wPjLxI47"&gt;Deferred
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deposits
from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when
cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily
convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue
item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Companys support and maintenance
services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various
customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $&lt;span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_c20210930_pp0p0" title="Deferred revenue"&gt;45,022&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--DeferredRevenueCurrent_c20201231_pp0p0" title="Deferred revenue"&gt;76,687&lt;/span&gt; as of
September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoyEeXfQLWtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z9DdplJkeAT1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, &lt;i&gt;Awards
Classified as Equity,&lt;/i&gt; which requires the measurement of compensation expense for all share-based compensation granted to employees
and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period
for awards expected to vest.The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock
options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected
stock price volatility of the Companys common stock, the risk free interest rate at the date of grant, the expected vesting term
of the grant, expected dividends, and an assumption related to forfeitures of such grants.Changes in these subjective input
assumptions can materially affect the fair value estimate of the Companys stock options and warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zDhTCNPcSeL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_znQeHywjaQr7"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Under
this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets
and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected
to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain
tax positions recognized in the Companys financial statements&lt;i&gt;.&lt;/i&gt; In accordance with this provision, tax positions must meet
a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax
position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z5exxHHnrha3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_znA54wOCBLI1"&gt;Fair
Value Measurements&lt;/span&gt; &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company adopted the provisions of ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The
carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations,
which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded
conversion options, are comparable to rates of returns for instruments of similar credit risk. The Companys investment in AHA
was valued at level 3 input.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1  quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2  quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3  inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_848_ecustom--ConvertibleInstrumentsPoliciesTextBlock_zW2zhiG4MGS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zQ86CyDz1Sl2"&gt;Convertible
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, &lt;i&gt;Derivatives
and Hedging Activities.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Applicable
GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative
financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and
risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host
contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at
fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same
terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated
from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value
of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at
the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements
are amortized over the term of the related debt to their stated date of maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zW1kiKzXLeCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zxG4DQ76lPT6"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
is generated by software licenses, training, and consulting. Software licenses are provided as SaaS-based subscriptions that grants access
to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on
a monthly-basis or task-basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration
of training and consulting projects are typically a few weeks or months and last no longer than 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SaaS-based
subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and
revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element
arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units
of accounting which are delivered items that have value to a customer on a standalone basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 1, 2019, the Company adopted the new revenue recognition standard Accounting Standards Update (ASU) 2014-09, Revenue
from Contracts with Customers (Topic 606), using the modified retrospective method. The modified retrospective adoption used by
the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit. Revenue from substantially
all the Companys contracts with customers continues to be recognized over time as performance obligations are satisfied. &lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides its customers with software licensing, training, and consulting through SaaS-based subscriptions. This subscription
revenue represents revenue earned under contracts in which the Company bills and collects the charges for licensing and related services.
The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identifying
                                            the contract with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identifying
                                            the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Determining
                                            the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Allocating
                                            the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues
from subscriptions are deferred and recorded as deferred revenue when cash payments are received in advance of the satisfaction of the
Companys performance obligations and recognized over the period in which the performance obligations are satisfied. The Company
completes its contractual performance obligations through providing its customers access to specified data through subscriptions for
a service period, and training on consulting associated with the subscriptions. The Company primarily invoices its customers on a monthly
basis and does not provide any refunds, rights of return, or warranties to its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHAs
performance obligation is to manage ACO participants who provide healthcare services to CMSs members for the purpose of generating
shared savings. If achieved, the Company receives shared savings payments from CMS, which represents variable consideration. The shared
savings payments are recognized using the most likely methodology. However, as the Company does not have sufficient insight from CMS
into the financial performance of the shared risk pool because of unknown factors related to shifting patient count, risk adjustment
factors and benchmark adjustments, among other factors, an estimate cannot be developed. Therefore, these amounts are considered to be
fully constrained and only recorded in the months when such payments are known and/or received. The Company generally receives payment
within ten months after the fiscal year-end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;AHP
negotiates fixed per-member, per-month (PMPM) rates (Capitation) with third-party insurers for a fixed period of time. The Independent
Physicians Association (IPA) recognizes capitation payments received in advance from third-party insurers as revenue on
a monthly basis without regard to the frequency, extent, or nature of the medical services actually furnished.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zwXebGwEdegg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_z4JCsuLQWVy7"&gt;Advertising
Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses advertising costs as incurred. Advertising costs of $&lt;span id="xdx_906_eus-gaap--AdvertisingExpense_c20210101__20210930_pp0p0" title="Advertising costs"&gt;21,154&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20200101__20200930_pp0p0" title="Advertising costs"&gt;41,418&lt;/span&gt; were charged to operations for the nine months
ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXJnGtHtdT08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zFs0qXSMXrC4"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect
is expected on the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f936" decimals="0" contextRef="c240" unitRef="usd">2795216.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:UseOfEstimates id="f937" contextRef="c5">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zHfbIJt67ASk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zeAhGN2S1ywl"&gt;Use
of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The
Companys significant estimates used in these financial statements include, but are not limited to, accounts receivable reserves,
the valuation allowance related to the Companys deferred tax assets, the recoverability and useful lives of long-lived assets,
debt conversion features, stock-based compensation, certain assumptions related to the valuation of the reserved shares and the assets
acquired and liabilities assumed related to the Companys acquisitions. Certain of the Companys estimates could be affected
by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external
factors could have an effect on the Companys estimates and could cause actual results to differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;







</us-gaap:UseOfEstimates>
  <us-gaap:Goodwill id="f938" decimals="0" contextRef="c240" unitRef="usd">31733526.0</us-gaap:Goodwill>
  <clinigence.com:CommonStockIssuedForAcquisitionOfSubsidiaries id="f939" decimals="0" contextRef="c5" unitRef="usd">68051012.0</clinigence.com:CommonStockIssuedForAcquisitionOfSubsidiaries>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="f940" decimals="0" contextRef="c237" unitRef="usd">39752.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:OtherAssets id="f941" decimals="0" contextRef="c240" unitRef="usd">38527782.0</us-gaap:OtherAssets>
  <clinigence.com:InvestmentInAhaInExchangeOfAssetsSoldAndLiabilitiesAssumed id="f942" decimals="0" contextRef="c12" unitRef="usd">6402278.0</clinigence.com:InvestmentInAhaInExchangeOfAssetsSoldAndLiabilitiesAssumed>
  <clinigence.com:VariableInterestEntityPolicyTextBlock id="f943" contextRef="c5">&lt;p id="xdx_843_ecustom--VariableInterestEntityPolicyTextBlock_z8Hb6s99Aqba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zgHV0MY8Ozwk"&gt;Variable
Interest Entities&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly-owned
by the Company in accordance with the consolidation guidance. The evaluation considers all of the Companys variable interests,
including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity
must meet both of the following criteria:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            entity has a legal structure that has been established to conduct business activities and
                                            to hold assets; such entity can be in the form of a partnership, limited liability company,
                                            or corporation, among others; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                            Company has a variable interest in the legal entity  i.e., variable interests that
                                            are contractual, such as equity ownership, or other financial interests that change with
                                            changes in the fair value of the entitys net assets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting.
If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model
if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities
that are not VIEs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.
The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.
The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s)
of voting rights); or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.
The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they
lack any of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.
The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entitys
economic performance, as evidenced by:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i.
Substantive participating rights in day-to-day management of the entitys activities; or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ii.
Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iii.
The obligation to absorb the entitys expected losses; or&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;iv.
The right to receive the entitys expected residual returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and
evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Variable
interest model&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis
is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company
 that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIEs economic
performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially
be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.
Refer to Note 17  Variable Interest Entities (VIEs) to the consolidated financial statements for information on
the Companys consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company
may account for the investment using the equity method of accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</clinigence.com:VariableInterestEntityPolicyTextBlock>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f944" decimals="0" contextRef="c240" unitRef="usd">108842.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <clinigence.com:CommonStockIssuedForSubscriptionsReceivable id="f945" decimals="0" contextRef="c5" unitRef="usd">4770000.0</clinigence.com:CommonStockIssuedForSubscriptionsReceivable>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="f946" decimals="0" contextRef="c240" unitRef="usd">6685414.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f947" decimals="0" contextRef="c240" unitRef="usd">2425112.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <clinigence.com:CommonStockIssuedForAcquisitionOfSubsidiaries id="f948" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:CommonStockIssuedForAcquisitionOfSubsidiaries>
  <us-gaap:ConsolidationPolicyTextBlock id="f949" contextRef="c5">&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zoyuoyo8SKme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zh62p15u3QMg"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clinigence Health, Inc., Accountable
Healthcare America Inc., and AHP Management Inc.All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
  <clinigence.com:RelatedPartyLoansConvertedToCommonStock id="f950" decimals="0" contextRef="c5" unitRef="usd">30000.0</clinigence.com:RelatedPartyLoansConvertedToCommonStock>
  <us-gaap:LiabilitiesCurrent id="f951" decimals="0" contextRef="c240" unitRef="usd">2470552.0</us-gaap:LiabilitiesCurrent>
  <clinigence.com:AccruedInterestConvertedToConvertibleNotesPayable id="f952" decimals="0" contextRef="c5" unitRef="usd">54746.0</clinigence.com:AccruedInterestConvertedToConvertibleNotesPayable>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f953" decimals="0" contextRef="c240" unitRef="usd">45440.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <clinigence.com:CommonStockIssuedForSubscriptionsReceivable id="f954" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:CommonStockIssuedForSubscriptionsReceivable>
  <clinigence.com:NotesPayableConvertedToAccountsPayable id="f955" decimals="0" contextRef="c5" unitRef="usd">228518.0</clinigence.com:NotesPayableConvertedToAccountsPayable>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="f956" contextRef="c5">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgHhl0EBCXmc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zs9zjVDf8ari"&gt;Property
and equipment and depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfEstimatedLivesOfRespectiveAssetsTableTextBlock_zBVPEhL1WJ04" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span id="xdx_8BE_zPGB96AYLX0h" style="display: none"&gt;Schedule of estimated lives of respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; width: 45%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    equipment and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zL4sqXuPn3T8" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zkSoJgJV5Exd" title="Office equipment useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    hardware&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareMember_z2esPoiBlkoa" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zETQaQPR7S5j" title="Office equipment useful life"&gt;3&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Development
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopmentEquipmentMember_zQ6fZwTK5E3a" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <clinigence.com:RelatedPartyLoansConvertedToCommonStock id="f957" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:RelatedPartyLoansConvertedToCommonStock>
  <clinigence.com:NotesPayableConvertedToCommonStock id="f958" decimals="0" contextRef="c5" unitRef="usd">1725000.0</clinigence.com:NotesPayableConvertedToCommonStock>
  <us-gaap:Assets id="f959" decimals="0" contextRef="c240" unitRef="usd">41690777.0</us-gaap:Assets>
  <us-gaap:Liabilities id="f960" decimals="0" contextRef="c240" unitRef="usd">2538434.0</us-gaap:Liabilities>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="f961" contextRef="c5">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zozxAnR2Bnbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zYNLbtspXHpe"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase.
The Company does not have any cash equivalents as of September 30, 2021 and December 31, 2020. The Company is exposed to credit risk
in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested
are in excess of amounts that are insured.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <clinigence.com:NotesPayableConvertedToAccountsPayable id="f962" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:NotesPayableConvertedToAccountsPayable>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="f963" contextRef="c241">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f964" decimals="0" contextRef="c240" unitRef="usd">67882.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <clinigence.com:ExchangeShares id="f965" decimals="INF" contextRef="c242" unitRef="shares">759036.0</clinigence.com:ExchangeShares>
  <clinigence.com:NotesPayableConvertedToCommonStock id="f966" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:NotesPayableConvertedToCommonStock>
  <clinigence.com:ScheduleOfEstimatedLivesOfRespectiveAssetsTableTextBlock id="f967" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfEstimatedLivesOfRespectiveAssetsTableTextBlock_zBVPEhL1WJ04" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span id="xdx_8BE_zPGB96AYLX0h" style="display: none"&gt;Schedule of estimated lives of respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; width: 45%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    equipment and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zL4sqXuPn3T8" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zkSoJgJV5Exd" title="Office equipment useful life"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    hardware&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareMember_z2esPoiBlkoa" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zETQaQPR7S5j" title="Office equipment useful life"&gt;3&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Development
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopmentEquipmentMember_zQ6fZwTK5E3a" title="Office equipment useful life"&gt;5&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:ScheduleOfEstimatedLivesOfRespectiveAssetsTableTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="f968" contextRef="c5">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z6FdHIvkanK" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
18  &lt;span id="xdx_82B_zemHUvsdnOr6"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company evaluated its September 30, 2021 condensed consolidated financial statements for subsequent events through the date the condensed
consolidated financial statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Business
Acquisition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 15, 2021, the Company entered into an agreement and plan of merger with Procare Health Inc. (Procare), a California
corporation, providing for the acquisition of 100% of the outstanding equity securities of Procare in exchange for &lt;span id="xdx_908_ecustom--ExchangeShares_c20211001__20211015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7Y8rlaHAWAd" title="Exchange shares"&gt;759,036 &lt;/span&gt;shares of
the Companys common stock. &lt;span style="background-color: white"&gt;Based in Garden Grove, California and founded in 2011, ProCare
is a leading management services organization (MSO) that currently provides services for one health maintenance organization
(HMO) and three independent physician associations (IPAs) in Southern and Northern California.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Conversions
of Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subsequent
to the end of the period through the date of the report, various noteholders converted $&lt;span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zhnZYyyyUO8a" title="Converted debt"&gt;670,000 &lt;/span&gt;of principal to &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zjnxe2PKVdDi"&gt;432,257 &lt;/span&gt;shares of the
Companys common stock, valued at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zNJ2uBP58tBa"&gt;1.55 &lt;/span&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock
Subscriptions Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subsequent
to the end of the period through the date of the report, the Company received the balance of stock subscriptions receivable of $&lt;span id="xdx_906_eus-gaap--CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_iI_c20210930_zHqwYbfzCAng" title="Stock Subscriptions Receivable"&gt;4,770,000&lt;/span&gt;
at September 30, 2021 from the stockholders, and paid $&lt;span id="xdx_90A_ecustom--PlacementAgentFees_iI_c20210930_zN4Qhx2BwRp1" title="Placement agent fees"&gt;217,000&lt;/span&gt; in placement agent fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subsequent
to the end of the period through the date of the report, the Company sold &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholderMember_pdd" title="Debt Conversion, Converted Instrument, Shares Issued"&gt;1,241,072&lt;/span&gt; shares of common stock to various investors valued
at $&lt;span id="xdx_904_eus-gaap--SharePrice_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pdd" title="Shares price"&gt;1.75&lt;/span&gt; per share for proceeds of $&lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Noteholder1Member_pp0p0" title="Debt Conversion, Converted Instrument, Amount"&gt;2,171,875&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;&lt;span style="text-decoration: none; font-style: normal; font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Sale of ACMG&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;On November 13, 2021 our subsidiary AHA,
as 29% shareholder of Sellers, entered into a Stock Purchase Agreement (the ACMG Agreement) by and among Genuine Health
Group, LLC (Buyer), Accountable Care Medical Group of Florida, Inc., a Florida corporation (Accountable Care Medical),
ACMG Health Group LLC, a Florida limited liability company (ACMG Group), and ACMG Health Systems, Inc., a Florida corporation
(ACMG Systems and collectively with Accountable Care Medical and ACMG Group, the Companies and each a Company),
each of the shareholders of Accountable Care Medical listed on Exhibit A of the ACMG Agreement (each a Seller and collectively
the Sellers), and Manuel Lopez, as Sellers Representative. The purchase price (&lt;span style="text-decoration: underline"&gt;Purchase Price&lt;/span&gt;)
to be paid by Buyer for the Equity Interests at Closing and all other rights and benefits conferred to Buyer herein, including, without
limitation, the representations, warranties and covenants set forth in this Agreement, shall be Thirty Million Dollars ($30,000,000.00)
less certain adjustments set forth in the Agreement. AHA shall be entitled to its 29% pro-rata portion of the purchase Price.&lt;/p&gt;
&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="f969" decimals="0" contextRef="c243" unitRef="usd">670000.0</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:SharePrice id="f970" decimals="INF" contextRef="c244" unitRef="usd1">1.55</us-gaap:SharePrice>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="f971" contextRef="c245">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <clinigence.com:DeferredTaxLiabilityRecordedOnIntangibleAssets id="f972" decimals="0" contextRef="c5" unitRef="usd">2429500.0</clinigence.com:DeferredTaxLiabilityRecordedOnIntangibleAssets>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="f973" contextRef="c246">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable id="f974" decimals="0" contextRef="c6" unitRef="usd">4770000.0</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
  <clinigence.com:ScheduleOfEstimatedLivesOfIntangibleAssetsTableTextBlock id="f975" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfEstimatedLivesOfIntangibleAssetsTableTextBlock_zafzW1UYLwI6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zQwIEYOvw22l" style="display: none"&gt;Schedule of estimated lives of the respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Population Health
    Platform technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_znDdkGe3rJNf" title="Intangible assets useful life"&gt;11&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zK0xXNDNGZSh" title="Intangible assets useful life"&gt;15&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zuBPXGw5vfo6" title="Intangible assets useful life"&gt;6&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;</clinigence.com:ScheduleOfEstimatedLivesOfIntangibleAssetsTableTextBlock>
  <clinigence.com:AccruedInterestConvertedToConvertibleNotesPayable id="f976" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:AccruedInterestConvertedToConvertibleNotesPayable>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="f977" contextRef="c247">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <clinigence.com:RightOfUseAssetAddedForOperatingLease id="f978" decimals="0" contextRef="c5" unitRef="usd">129971.0</clinigence.com:RightOfUseAssetAddedForOperatingLease>
  <clinigence.com:DebtDiscountsOnNotesPayable id="f979" decimals="0" contextRef="c5" unitRef="usd">659755.0</clinigence.com:DebtDiscountsOnNotesPayable>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="f980" contextRef="c248">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <clinigence.com:RightOfUseAssetAddedForOperatingLease id="f981" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:RightOfUseAssetAddedForOperatingLease>
  <clinigence.com:AmortizationPolicyTextBlock id="f982" contextRef="c5">&lt;p id="xdx_84F_ecustom--AmortizationPolicyTextBlock_zfErM7Ncqmee" style="font: 10pt Times New Roman, Times, Serif; margin: 13.5pt 0 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zvNIWl97Ulcd"&gt;Amortization&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets are amortized using the straight line method over the estimated lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfEstimatedLivesOfIntangibleAssetsTableTextBlock_zafzW1UYLwI6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zQwIEYOvw22l" style="display: none"&gt;Schedule of estimated lives of the respective assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Population Health
    Platform technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PopulationHealthPlatformTechnologyMember_znDdkGe3rJNf" title="Intangible assets useful life"&gt;11&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zK0xXNDNGZSh" title="Intangible assets useful life"&gt;15&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zuBPXGw5vfo6" title="Intangible assets useful life"&gt;6&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</clinigence.com:AmortizationPolicyTextBlock>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="f983" decimals="INF" contextRef="c243" unitRef="shares">432257.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <clinigence.com:DeferredTaxLiabilityRecordedOnIntangibleAssets id="f984" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:DeferredTaxLiabilityRecordedOnIntangibleAssets>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="f985" contextRef="c167">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <clinigence.com:PlacementAgentFees id="f986" decimals="0" contextRef="c6" unitRef="usd">217000.0</clinigence.com:PlacementAgentFees>
  <clinigence.com:DebtDiscountsOnNotesPayable id="f987" decimals="0" contextRef="c12" unitRef="usd">0.0</clinigence.com:DebtDiscountsOnNotesPayable>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f988" decimals="0" contextRef="c249" unitRef="usd">3195000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f989" decimals="0" contextRef="c250" unitRef="usd">3193174.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <clinigence.com:NotesPayableConvertedToCommonStockShares id="f990" decimals="INF" contextRef="c79" unitRef="shares">128672.0</clinigence.com:NotesPayableConvertedToCommonStockShares>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f991" decimals="0" contextRef="c250" unitRef="usd">-319500.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaise>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f992" decimals="0" contextRef="c249" unitRef="usd">-319500.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaise>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f993" decimals="0" contextRef="c249" unitRef="usd">200000.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f994" decimals="0" contextRef="c250" unitRef="usd">199871.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f995" decimals="0" contextRef="c79" unitRef="usd">129.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <us-gaap:ProfitLoss id="f996" decimals="0" contextRef="c133" unitRef="usd">-2738511.0</us-gaap:ProfitLoss>
  <clinigence.com:DebtDiscountOnNotesPayable id="f997" decimals="0" contextRef="c250" unitRef="usd">659755.0</clinigence.com:DebtDiscountOnNotesPayable>
  <clinigence.com:DebtDiscountOnNotesPayable id="f998" decimals="0" contextRef="c249" unitRef="usd">659755.0</clinigence.com:DebtDiscountOnNotesPayable>
  <us-gaap:ProfitLoss id="f999" decimals="0" contextRef="c144" unitRef="usd">-49929.0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="f1000" decimals="0" contextRef="c249" unitRef="usd">-2788440.0</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="f1001" decimals="INF" contextRef="c251" unitRef="shares">41250118.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1002" decimals="0" contextRef="c251" unitRef="usd">41250.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1003" decimals="0" contextRef="c252" unitRef="usd">92712821.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1004" decimals="0" contextRef="c253" unitRef="usd">-25402032.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1005" decimals="0" contextRef="c254" unitRef="usd">-89510.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1006" decimals="0" contextRef="c255" unitRef="usd">67262529.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <clinigence.com:CommonStockSubscribed id="f1007" decimals="0" contextRef="c166" unitRef="usd">2011.0</clinigence.com:CommonStockSubscribed>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f1008" decimals="INF" contextRef="c166" unitRef="shares">2392679.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f1009" decimals="0" contextRef="c166" unitRef="usd">2392.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f1010" decimals="0" contextRef="c256" unitRef="usd">4184171.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f1011" decimals="0" contextRef="c1" unitRef="usd">4186563.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f1012" decimals="0" contextRef="c256" unitRef="usd">-358500.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaise>
  <clinigence.com:PaymentsOfFinancingCostsForCapitalRaise id="f1013" decimals="0" contextRef="c1" unitRef="usd">-358500.0</clinigence.com:PaymentsOfFinancingCostsForCapitalRaise>
  <clinigence.com:CommonStockSharesSubscribed id="f1014" decimals="INF" contextRef="c166" unitRef="shares">2011428.0</clinigence.com:CommonStockSharesSubscribed>
  <clinigence.com:NotesPayableConvertedToCommonStockShares id="f1015" decimals="INF" contextRef="c166" unitRef="shares">804570.0</clinigence.com:NotesPayableConvertedToCommonStockShares>
  <clinigence.com:CommonStockSubscribed id="f1016" decimals="0" contextRef="c1" unitRef="usd">4770000.0</clinigence.com:CommonStockSubscribed>
  <clinigence.com:CommonStockSubscribed id="f1017" decimals="0" contextRef="c256" unitRef="usd">4767989.0</clinigence.com:CommonStockSubscribed>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants id="f1018" decimals="INF" contextRef="c166" unitRef="shares">48750.0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f1019" decimals="0" contextRef="c166" unitRef="usd">805.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f1020" decimals="0" contextRef="c256" unitRef="usd">1524195.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <clinigence.com:NotesPayableConvertedToCommonStockValue id="f1021" decimals="0" contextRef="c1" unitRef="usd">1525000.0</clinigence.com:NotesPayableConvertedToCommonStockValue>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisitionShares id="f1022" decimals="INF" contextRef="c166" unitRef="shares">-1076372.0</clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisitionShares>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="f1023" decimals="0" contextRef="c1" unitRef="usd">60937.0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="f1024" decimals="0" contextRef="c256" unitRef="usd">60888.0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="f1025" decimals="0" contextRef="c166" unitRef="usd">49.0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="f1026" decimals="INF" contextRef="c166" unitRef="shares">164143.0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1027" decimals="0" contextRef="c1" unitRef="usd">174247.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1028" decimals="0" contextRef="c256" unitRef="usd">174247.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition id="f1029" decimals="0" contextRef="c1" unitRef="usd">-2217326.0</clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition id="f1030" decimals="0" contextRef="c256" unitRef="usd">-2216250.0</clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition>
  <clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition id="f1031" decimals="0" contextRef="c166" unitRef="usd">-1076.0</clinigence.com:ReturnOfCommonStockHeldBackInAhpAcquisition>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f1032" decimals="0" contextRef="c166" unitRef="usd">164.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f1033" decimals="0" contextRef="c256" unitRef="usd">337971.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="f1034" decimals="0" contextRef="c1" unitRef="usd">338135.0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:ProfitLoss id="f1035" decimals="0" contextRef="c153" unitRef="usd">-1903820.0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="f1036" decimals="0" contextRef="c160" unitRef="usd">101853.0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="f1037" decimals="0" contextRef="c1" unitRef="usd">-1801967.0</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="f1038" decimals="INF" contextRef="c257" unitRef="shares">45595316.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1039" decimals="0" contextRef="c257" unitRef="usd">45595.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1040" decimals="0" contextRef="c258" unitRef="usd">101187532.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1041" decimals="0" contextRef="c259" unitRef="usd">-27305852.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1042" decimals="0" contextRef="c260" unitRef="usd">12343.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding id="f1043" decimals="INF" contextRef="c261" unitRef="shares">4649179.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1044" decimals="0" contextRef="c261" unitRef="usd">4649.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1045" decimals="0" contextRef="c262" unitRef="usd">14422579.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1046" decimals="0" contextRef="c263" unitRef="usd">-12568795.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1047" decimals="0" contextRef="c43" unitRef="usd">1858433.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1048" decimals="0" contextRef="c197" unitRef="usd">848778.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1049" decimals="0" contextRef="c264" unitRef="usd">848778.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:ProfitLoss id="f1050" decimals="0" contextRef="c188" unitRef="usd">-1122730.0</us-gaap:ProfitLoss>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f1051" decimals="0" contextRef="c190" unitRef="usd">1170.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f1052" decimals="0" contextRef="c264" unitRef="usd">1170.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:ProfitLoss id="f1053" decimals="0" contextRef="c264" unitRef="usd">-1122730.0</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="f1054" decimals="INF" contextRef="c265" unitRef="shares">4649179.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1055" decimals="0" contextRef="c265" unitRef="usd">4649.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1056" decimals="0" contextRef="c266" unitRef="usd">15271357.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1057" decimals="0" contextRef="c267" unitRef="usd">-13691525.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1058" decimals="0" contextRef="c268" unitRef="usd">-1170.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="f1059" decimals="0" contextRef="c269" unitRef="usd">1583311.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="f1060" decimals="INF" contextRef="c200" unitRef="shares">225820.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <clinigence.com:OptionsIssuedForServicesValue id="f1061" decimals="0" contextRef="c270" unitRef="usd">1056599.0</clinigence.com:OptionsIssuedForServicesValue>
  <clinigence.com:OptionsIssuedForServicesValue id="f1062" decimals="0" contextRef="c84" unitRef="usd">1056599.0</clinigence.com:OptionsIssuedForServicesValue>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1063" decimals="0" contextRef="c200" unitRef="usd">226.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1064" decimals="0" contextRef="c270" unitRef="usd">361086.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="f1065" decimals="0" contextRef="c84" unitRef="usd">361312.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f1066" decimals="0" contextRef="c" unitRef="usd">1170.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f1067" decimals="0" contextRef="c84" unitRef="usd">1170.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
</xbrli:xbrl>
